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Introduction
Vestibular schwannoma (VS) is a benign neoplasm recapitulating the differentiation 
repertoire of the myelin-forming Schwann cells forming the nerve sheath that insulates the 
vestibular portion of the eighth cranial nerve. Other more archaic names used to designate 
this tumor are acoustic neuroma, acoustic neurinoma or vestibular neuroma. Given its origin 
and biological composition, vestibular schwannoma is the most appropriate terminology1,2. 
Though benign these tumors are not harmless, their location in the internal auditory meatus 
and cerebellopontine angle can cause severe morbidity and in rare cases may even lead 
to death by brainstem compression when they are left untreated. 
VS account for approximately 80% of all neoplastic lesions found in the cerebellopontine 
angle (CPA) 3. Approximately 90% of all VS are unilateral sporadic tumors 4. In rare cases 
these tumors occur bilateral which is a pathognomonic symptom for the hereditary disease 
neurofibromatosis type 2 (NF2). Recent years the number of diagnosed VS is rising. This 
rise is largely a result of the increased application of magnetic resonance imaging (MRI) 
scanning which for example leads to the detection of more asymptomatic lesions. Next to 
its widespread use the continually improving sensitivity of MRI is an important contributor 
to this phenomenon as well. The current incidence rate of VS lies around 20 per million 
people per year and this number is still increasing5-8. 
The biological background of schwannomas is still not fully understood. An important step 
in unravelling the genetic basis of VS formation was made by Rouleau, Seizinger and 
Trofatter who isolated the neurofibromatosis type-2 gene (NF2) during the late 80’s of the 
twentieth century 9-12. The NF2 gene is located on chromosome 22q11 and it encodes for 
the tumor suppressor protein merlin 13. Heterozygous germline inactivating mutations 
affecting NF2 cause neurofibromatosis type-2 while biallelic somatic mutations of NF2 are 
found in sporadic, unilateral vestibular schwannomas. 14 
This thesis mainly comprises research that is performed on sporadic vestibular 
schwannomas. NF2-related and sporadic vestibular schwannomas show considerable 
differences in their clinical presentation and they often require different and more complex 
therapeutic approaches. At the same time there are quite some similarities between both 
tumors and biological or clinical knowledge about one type can be beneficial to the 
understanding of tumorgenesis of the other type as well. 
Unilateral vestibular schwannomas usually occur in adult patients with a peak incidence 
ranging from forty to sixty years 4,15 Main clinical symptoms are unilateral sensorineural 
hearing loss, tinnitus and balance disorders. In rare cases larger tumors can cause 
unsteadiness, trigeminus neuralgia, facial nerve paralysis and long tracks symptoms. If 
untreated, progressive tumors can finally lead to brain stem compression, obstructive 
hydrocephalus and increased intracranial pressure. 
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During the 20th century the tools and techniques to detect vestibular schwannomas have 
greatly improved from the tunic fork to audiometry and vestibular testing, auditory brain stem 
evoked response testing, computed tomography and finally magnetic resonance imaging 
(MRI)16. In 1987 gadolinium enhanced MRI was introduced, this technique has become the 
gold standard for the diagnosis of VS 17. Tumors as small as 3 mm can now be detected 18. 
The ability to detect VS in an ever-earlier phase has led to an increasingly complex decision-
making regarding the best way to deal with these tumors once they are diagnosed. 
Therapeutic management
Current therapeutic management of sporadic VS comprises three main options: conservative 
management by observation with scheduled MRI follow-up (wait-and-scan), microsurgery 
or radiotherapy. Although scarcely applied and not part of standard therapy yet, 
pharmacotherapeutic options are emerging as well. Choosing the most suitable therapy is 
mainly based on symptoms, radiological assessment and patient’s preference. 
Observation
Because of the increase in use and quality of MRI more and more VS are diagnosed in 
early tumor stages, often without even causing symptoms. Given the fact that VS are 
relatively slow growing tumors with an average growth rate of approximately  1-3 mm/year 
19-21 the initial treatment strategy in these cases will be observation. This strategy was first 
suggested for the elderly or otherwise frail patients. Because natural history studies have 
indicated that up to 50% of VS show no significant growth in the first five years after 
diagnosis 19 this strategy nowadays is applied to younger patients as well. The goal of this 
strategy is to delay or even avert treatment related morbidity. The main drawback of this 
policy is that in case of rapid tumor progression the complexity of active treatment will have 
increased compared to the conditions at initial diagnosis. One of the hallmarks of VS is 
their variable growth pattern. This makes prediction of future tumor behavior difficult and 
even a strict wait and scan protocol with systematic radiological follow-up can sometimes 
result in unexpected and unfavorable situations. Better understanding of the biological 
processes behind VS growth can help to improve prediction of tumor behavior in order to 
single out potentially aggressive tumors at an early stage.  
Microsurgery
First successful attempts to surgically remove VS were performed over a century ago. 
Unfortunately, these pioneering surgeons accomplished success in a minority of cases. 
Shortly before the start of World War One mortality rates were approximately 80% and 
almost all patients suffered major complications 22. Over the twentieth century surgical 
outcomes have greatly improved. A large contribution to this growing success rate was the 
application of the translabyrinth microsurgical approach introduced by the otologist House 
13
Introduction and outline of the thesis
1
in 1963. Current reviews indicate that mortality associated with VS surgery is rare and 
occurs in less than 1%  of cases 23. Microsurgical techniques provide good tumor control 
but there is still an undeniable risk of iatrogenic complications such as damage to adjacent 
cranial nerves, cerebrospinal fluid leak, intracranial hemorrhage and meningitis. So far, 
microsurgery is the only treatment strategy to achieve (near total) tumor removal while 
radiotherapeutic approaches merely prevent additional tumor growth. Surgery has a high 
efficacy  and less than 1% of patients require additional treatment after incomplete tumor 
resection23. Because of the significant risks associated with microsurgery it is important that 
patients and physicians make a balanced decision in which benefits have to be weighed 
against potential complications. Main indications to apply microsurgery should be tumors 
that progress rapidly or large tumors (>30mm) showing radiological or clinical signs of 
brainstem compression. 
Radiotherapy 
The Swedish neurosurgeon Lars Leksell introduced the concept of stereotactic radiosurgery 
(SRS) for brain tumors in 1951. The first time this technique, also known as the Gamma 
Knife, was applied to a VS was in 1969 24. Initially high-dose treatment protocols were used. 
This led to good tumor control but also had a significant effect on hearing loss and rates of 
facial and trigeminal neuropathy were high. Over the years the dose threshold has been 
lowered to 12 or even 11 Gy. At these levels permanent facial palsy is less than 1% and 
over 90% of patients show durable tumor control25.  Recent years another type of particle 
therapy, proton therapy, is increasingly used. This technique uses protons instead of photons 
and has the advantage of further reducing the radiation dose to surrounding tissues, 
hypothetically leading to less iatrogenic damage. It used to be a scarce treatment modality 
but the availability has increased tremendously during the past decades. A recent article 
reviewing proton therapy indicated that data on its application in VS treatment is scarce 
and the few reports that are present do not show a favorable outcome in comparison to 
conventional radiotherapy26,27. The role of proton therapy in the treatment of VS remains 
unclear and additional research is needed to properly verify its effect before making it part 
of standard treatment options.
Pharmacotherapy
Despite the improvements of surgical and radiotherapeutical techniques these modalities 
will always carry a certain risk of inflicting iatrogenic damage to surrounding structures. 
Pharmacotherapeutic treatment might be an additional treatment strategy with less 
iatrogenic effects or complications. It could also benefit patients that are not eligible to 
undergo current forms of therapy. 
Treating sporadic VS with drugs is not part of standard clinical practice yet. Nevertheless 
there are promising reports on the effect of antiangiogenic treatments for patients suffering 
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from NF2 related vestibular schwannomas. The most extensively tested drug in the context 
of VS is bevacizumab. This is an U.S. Food and Drug Administration approved anti-VEGF 
antibody used for the treatment of several types of cancer. A number of reports demonstrated 
stabilization and even tumor shrinkage in a significant amount of patients 28 29,30. Other forms 
of targeted therapy showed encouraging results as well 31 but there are also reports on drug 
resistant tumors32. Chapter two provides a more extensive overview of the current knowledge 
on-, and the future prospectives of pharmacologic therapies and the tumor biological 
processes behind them. The genetic- and micro environmental factors that determine 
vestibular schwannoma genesis and development will be discussed in chapter two as well. 
Choice of therapy
Choosing the most suitable therapy for individual vestibular schwannoma patients can be 
a complex matter. In the obvious cases, such as fragile patients with small and stable 
intracanalicular tumors or young patients with progressing large brainstem compressing 
tumors, the choice can be quite clear. However, most patients find themselves between 
these extreme ends of the spectrum. For this category of patients there is the possibility to 
choose between different treatment modalities. This choice has to be made by the patient 
together with his or her physician. The fact that even among experts there remains 
controversy when it comes to selecting the correct therapy makes shared-decision-making 
even more difficult. During the past decades a vast amount of research into this topic has 
been performed but so far a balances consensus has yet to be reached. 
The fact that all modalities have different goals makes a correct comparison between them 
difficult. For microsurgery an important goal is total tumor removal, for radiosurgery stopping 
tumor progression is the main outcome to measure success while the desired result of the 
wait and scan policy is avoiding disproportional treatment related morbidity. Before reaching 
consensus about treatment there should be more consensus about the goals and criteria 
by which success can be defined. A more general method to assess the effect of treatment 
is to determine quality of life (QoL). The PhD theses of Godefroy in 2010 and van Leeuwen 
in 2016, both at the Leiden University, indicated the importance of this measuring instrument. 
QoL assessments can help to increase the comparability of the therapeutic modalities, this 
will benefit the research that is performed to refine the decision-making with regard to the 
correct timing and method of treatment. Another factor that complicates the controversy 
regarding the choice of therapy is the unpredictable behavior of VS. As mentioned earlier, 
for the cases at both ends of the phenotypic spectrum the required treatment strategy can 
be obvious. Unfortunately in a large proportion of patients, often the ones with medium 
sized tumors, it is difficult to make a good prognosis of future tumor growth. The controversy 
over the choice of therapy is most evident in this category of patients. 
Increased accuracy of predicting tumor growth will help to narrow down the group of patients 
for whom it is unclear which therapy will benefit them the most. So far the only proven 
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prognostic factors of tumor growth are observed growth during follow-up and cystic 
degeneration 21,33. More insight into the tumor biology of VS improves the understanding of 
its growth pattern, which in turn benefits the search for better prognostic factors of tumor 
growth. A recent example of research with a similar purpose was the identification of loss 
of H3K27 tri-methylation as a prognostic marker for malignant peripheral nerve sheath 
tumors34. Next to improving the accuracy of predicting tumor progression, tumor biological 
research has the goal of identifying potential targets for pharmacotherapy. The current 
thesis can be seen in this context. 
Aims and outline of the thesis
In this thesis a number of tumor biological characteristics of sporadic VS are analyzed. We 
mainly focus on prognostic markers which could benefit individual decision making and 
processes that can form a potential target for therapy. Prior tumor biological research on 
VS has predominantly been performed on neurofibromatosis type 2 related tumors, sporadic 
tumors have been studied to a much lesser extent. Chapter 2 provides an overview of the 
tumor biological research that has been performed on both types of VS but it focusses on 
the sporadic tumors. Current knowledge about the genetic profile of VS is described and 
the roles of angiogenesis and the microenvironment on tumor progression are discussed. 
It also comprises a summary of targeted therapy that has been applied so far. 
Chapter 3 presents an immunohistochemical analysis of the presence of markers for cell 
proliferation (Histone H3 and Ki-67), vascularization (CD31), inflammation (CD45 and CD68) 
and intratumoral bleeding (hemosiderin).  The expression of these markers was correlated 
to clinical parameters such as tumor size, patient age at time of surgery and duration of 
symptoms. 
Chapter 4 describes an allele specific quantitative real-time PCR assay that was performed 
on tumor specimens of forty-eight patients in order to detect the presence of the thirteen 
most frequent mutations affecting BRAF, EGFR, PIK3CA, and KRAS. These genes encode 
for proteins that are members of the MAPK/ERK cell signaling pathway which is associated 
with uncontrolled cell growth. This pathway is known to be up regulated in VS and BRAF 
mutations have already been found in other sporadic non-head and neck schwannomas. 
If present, mutated BRAF can function as a potential target for therapy.
 In chapter 5 the inflammatory microenvironment of vestibular schwannomas is investigated 
by analyzing the presence of tumor associated macrophages (TAM).  These macrophages 
are known to support tumor progression by stimulating processes like angiogenesis. The 
presence of TAM is analyzed by immunofluorescent staining for CD163. The level of CD163 
expression is assessed and compared with the degree of angiogenesis and tumor growth 
in 20 sporadic vestibular schwannomas. 
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In chapter 6 the expression of the breast cancer resistance protein BCRP is studied in a 
selection of peripheral nerve sheath tumors i.e. vestibular schwannomas, plexiform 
neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs). All three tumor 
subtypes are known to display a certain degree of intrinsic resistance to drug therapy. BCRP 
is a transmembrane efflux transporter associated with drug resistance in various types of 
cancer and it is also part of the blood-brain-barrier. Targeting BCRP can enhance drug 
susceptibility of neoplastic tissues.  In order to investigate the role of this protein in the 
biology of peripheral nerve sheath tumors an immunohistochemical staining for BCRP is 
performed on a tissue microarray. This array comprises 22 sporadic vestibular schwannomas, 
10 plexiform neurofibromas and 18 MPNSTs. 
Chapter 7 elaborates on the inflammatory microenvironment by investigating the 
macrophage colony stimulating factor (M-CSF) and interleukin-34 (IL-34). These two 
cytokines play a key role in the recruitment of TAMs and thereby form a potential therapeutic 
target. An immunohistochemical analysis of these proteins is performed in the same patient 
cohort as described in chapter 4. The presence of M-CSF and IL-34 will be related to the 
presence of TAMs, the degree of angiogenesis and volumetric tumor growth. Finally the 
results of the thesis are summarized and discussed in chapter 8, and future perspectives 
for research are indicated. 
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Tumor Biology of Vestibular Schwannoma:
A Review of Experimental Data on the Determinants
of Tumor Genesis and Growth Characteristics
CHAPTER 2
Abstract
Objective: provide an overview of the literature on vestibular schwannoma biology with 
special attention to tumor behavior and targeted therapy.
Background: vestibular schwannomas are benign tumors originating from the eighth cranial 
nerve and arise due to inactivation of the NF2 gene and its product merlin. Unraveling the 
biology of these tumors helps to clarify their growth pattern and is essential in identifying 
therapeutic targets.
Methods: PubMed search for English language articles on vestibular schwannoma biology 
from 1994 till 2014.
Results: activation of merlin and its role in cell signaling seem key aspects of vestibular 
schwannoma biology. Merlin is regulated by proteins like CD44, Rac and myosin 
phosphatase targeting subunit 1 (MYPT1). The tumor suppressive functions of merlin are 
related to receptor tyrosine kinases, such as the platelet-derived growth factor receptor 
(PDGFR) and vascular endothelial growth factor receptor (VEGF). Merlin mediates the 
Hippo pathway and acts within the nucleus by binding E3 ubiquiting ligase CRL4DCAF1. 
Angiogenesis is an important mechanism responsible for the progression of these tumors 
and is affected by processes like hypoxia and inflammation. Inhibiting angiogenesis by 
targeting VEGF seems to be the most successful pharmacological strategy but additional 
therapeutic options are emerging. 
Conclusion: over the years the knowledge on vestibular schwannoma biology has 
significantly increased. Future research should focus on identifying new therapeutic targets 
by investigating vestibular schwannoma (epi)genetics, merlin function and tumor behavior. 
Besides identifying novel targets, testing new combinations of existing treatment strategies 
can further improve vestibular schwannoma therapy.
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Introduction
Sporadic vestibular schwannomas (VS) are benign tumors recapitulating the differentiation 
repertoire of the myelin-forming Schwann cells of the vestibular branch of the eighth cranial 
nerve. Vestibular schwannomas derive within the internal auditory canal, often extending 
into the cerebellopontine angle. Associated symptoms are hearing loss, tinnitus and vertigo. 
Large tumors can cause paralysis of adjacent cranial nerves and brainstem compression. 
The majority of vestibular schwannomas occur as unilateral sporadic tumors(>90%)1. 
Bilateral tumors are pathognomonic for the hereditary disorder neurofibrosis type 2 (NF2). 
In this review we discuss both but mainly focus on the sporadic tumors. Recent years the 
incidence of vestibular schwannomas has increased to approximately 20 per million people 
per year 2-4. This is probably a consequence of the increased application of magnetic 
resonance imaging (MRI) scanning resulting in the identification of more subclinical cases. 
Therapeutic management of vestibular schwannomas comprises three strategies i.e. 
microsurgery, radiotherapy or serial radiological observation. So far pharmacological 
treatment options are scarce 5-7. An important aspect determining the most suitable therapy 
is growth rate. Some tumors remain stable for years while others grow relatively fast (Figure 
1.) The biological background of this phenotypical heterogeneity is largely unknown. This 
review provides an overview of the literature on vestibular schwannoma biology with special 
attention to tumor behaviour and targeted therapy. 
Figure 1. Sequential T1-weighted gadolinium enhanced magnetic resonance imaging scans of a fast-growing sporadic 
VS. This tumor more than doubled in volume from 4.25 ml (A) to 11.75 ml (B) in less than 10 months causing 




An essential contribution to the understanding of vestibular schwannoma biology was the 
isolation of the neurofibromatosis type-2 gene (NF2) 8,9. NF2 encodes for the tumor 
suppressor protein merlin. This gene is located on chromosome 22q12 and contains 17 
exons. Loss of functional merlin is essential in schwannoma pathogenesis 10. Heterozygous 
germline inactivating mutations affecting NF2 cause the autosomal dominant disorder 
neurofibrosis type-2 and biallelic somatic mutations of NF2 are found in sporadic vestibular 
schwannomas 11. 
Merlin Structure and Activation
Merlin is a cytoskeletal protein encoded by the NF2 gene. It shows similarity to the ERM 
proteins, ezrin, radixin and moesin. These proteins play an important role in linking the actin 
cytoskeleton with plasma membranes 12. “Merlin” is an acronym for “Moesin-Ezrin-Radixin-
like Protein”. Merlin consists of an relatively conserved N-terminal FERM (Four-point-one, 
ezrin, radixin, moesin) domain followed by a coil-coil domain and a Carboxyl-terminal 
domain 13 (Figure 2).  
The FERM domain is a membrane-binding module resembling the domain of the ERM 
proteins except for the C-terminal domain which lacks an actin-binding motif 14-16. Instead, 
merlin directly binds actin with residues in the glutathione S-transferase N-terminal domain 
17 or indirectly in association with II-spectrin or fodrin 18.
Merlin exists in an open and closed state. Dephosphorylation of merlin causes the protein 
to close. The closed conformation of merlin is the active tumor suppressor 19-21. Promitogenic 
signals initiated by membrane-bound integrins and receptor tyrosine kinases are transduced 
by the signalling protein Rac which in turn activates p21-activated kinase (PAK) 22,23. 
Activated PAK phosphorylates merlin at amino acid serine 518 19,24,25. This phosphorylation 
induces an open conformation of merlin, thereby inhibiting its tumor suppressor function. 
In addition to PAK merlin is also phosphorylated by protein kinase A (PKA)26. PKA mediated 
phosphorylation not only takes place at serine 518 but serine 10 as well 27. The effect of 
phosphorylation at serine 10 is not entirely clear but it is suggested to induce changes of 
the actin cytoskeleton. 
Conversely to Rac, engagement of cadherins or loss of mitogenic signalling inactivates 
PAK, leading to increased levels of closed, activated merlin 22. In accordance with these 
observations, inactivation of merlin leads to loss of contact inhibition 28,29 and accelerated 
progression of the cell cycle 30. By combining signals from cadherins and integrins merlin 
mediates cell cycle progression. 
Another regulator of merlin is CD44, a transmembrane hyaluronic acid receptor involved 
in cell adhesion, matrix adhesion and cell migration 31. Merlin mediates contact inhibition 
dependent cell growth by its interaction with CD44. Through these interactions merlin and 
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CD44 may function as a switch controlling cell growth arrest or proliferation 32,33. Merlin can 
also be activated by myosin phosphatase targeting subunit 1 (MYPT1). This protein 
dephosphorylates merlin at amino acid serine 518 20,34. The concept of MYPT1 mediated 
activation of merlin is supported by the observation that CPI-17 (protein kinase C-potentiated 
phosphatase inhibitor of 17 kDa), a cellular inhibitor of MYPT1, causes loss of function of 
merlin 34. Figure 3 provides an overview of various interactions involved in merlin regulation. 
Merlin’s role in cell signalling 
Contact mediated inhibition is an important mechanism regulating cell growth. The tumor 
suppressive role of merlin seems largely affect by contact inhibition 23,32,35,36. Identifying 
cellular pathways in which merlin participates may provide targets for treatment. Examples 
of targeted therapy are tyrosine kinase inhibitors, which have been successfully employed 
for solid neoplasms like gastrointestinal stromal tumors as well as leukemia’s37,38. Tyrosine 
kinases are enzymes involved in the activation of numerous cell signalling cascades, when 
inhibited they can slow down or arrest tumor progression. It is because of developments 
like these that a significant proportion of schwannoma related research is now devoted to 
clarifying the function of merlin and the cell signalling pathways it affects. To maintain 
comprehensibility only the most well-established interactions will be discussed.
Figure 2. Merlin structure. Merlin has three structural sections: the N-terminal FERM domain followed by a coil-coil 
domain and a Carboxyl-terminal domain. Dephosphorylation of merlin at amino acid Serine 518 causes the protein 
to fold and become active
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Merlin’s tumor suppressor function is linked to the integrin mediated Rac pathway, which 
is involved in actin remodelling, cell cycle control, transcription and apoptosis. Shaw et al. 
19 were the first to describe this association. They demonstrated merlin’s ability to negatively 
regulate Rac, this was confirmed by additional studies 23,39. A downstream target of Rac is 
PAK, the kinase responsible for the activation of merlin. The interaction between merlin, 
Rac and PAK suggests a positive feedback loop between merlin and PAK.
Merlin has been proposed to suppress proliferation by inhibiting receptor tyrosine kinases 
(RTKs) including the ErbB receptors, the platelet-derived growth factor receptor (PDGFR), 
the insulin-like growth factor 1 receptor (IGF1R) and the vascular endothelial growth factor 
(VEGF) receptor 28,35,40-42. This is confirmed by the fact that proteins of the oncogenic Ras/
Raf/MEK/ERK and PI3K/AKT pathways, which are downstream of these RTKs, are strongly 
activated in merlin deficient schwannoma cell models 43,44. 
Merlin seems to act as a negative regulator of the mammalian target of rapamycin complex 
1 (mTORC1), a kinase complex that regulates cell growth, cell proliferation, cell motility and 
cell survival 45. mTORC1 seems activated in merlin deficient meningioma cells 46. This is 
Figure. 3. Merlin activation. Cell-to-cell adhesions and CD44 activate MYPT1, which dephosphorylates merlin resulting 
in a closed and active protein conformation. Conversely, integrins and receptor tyrosine kinases activate Pak, which 
phosphorylates merlin, inducing an open and inactivated confirmation.
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supported by the correlation between loss of merlin and mTORC1 activation observed in 
mesothelioma cell lines 30. The significance of mTORC1 as an effector of merlin is 
emphasized by the fact that the mTOR kinase inhibitor, Torin 1, could successfully block 
mTORC1 and AKT in merlin deficient meningioma cells leading to inhibited cell proliferation47. 
See figure 4 for an overview of kinases affected by merlin. 
Merlin also mediates the Hippo pathway. This pathway controls organ size through regulation 
of cell proliferation and apoptosis. Mutations affecting this pathway are associated with 
different types of cancer 48. A study investigating Hippo signalling in Drosophila showed that 
merlin is required for cell proliferation arrest and apoptosis 49. This observation is supported 
by studies on meningioma cell lines and primary meningioma tumors which demonstrated 
that merlin suppresses the oncoprotein YAP (Yes-associated protein), a member of the 
Hippo pathway capable of stimulating cell proliferation 50,51. 
Most of merlin’s interactions take place around the plasma membrane. A recent study 
showed that merlin also accumulates in the nucleus where it binds the E3 ubiquitin ligase 
CRL4DCAF1 blocking its activity 52-54. CRL4DCAF1 has been implicated to induce an elaborate 
oncogenic program of gene expression 55. Interactions between merlin and CRL4DCAF1 seem 
to be essential for tumor suppression by merlin. 
Figure 4. Merlin signalling. Merlin is proposed to suppress proliferation by inhibiting several receptor tyrosine kinases 
and their downstream signalling pathways. 
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NF2 mutations in sporadic VS
To date, the genetic profile of vestibular schwannomas has not been fully characterized. 
The only consistent genetic alteration is inactivation of the NF2 gene. Multiple mutation 
analyses screening for NF2 mutations in sporadic vestibular schwannomas have been 
described. Reports on the number of tumors containing a proven NF2 mutation range from 
15 to 84% (table 1). Most mutations are small deletions and point mutations 56-61, resulting 
in truncated proteins. A significant proportion of vestibular schwannomas did not harbour 
a proven NF2 mutation. Studies investigating the NF2 gene product, both at RNA- as well 
as protein level, demonstrated decreased expression of NF2 gene products in a much 
higher percentage of tumors then expected with regard to the percentage of tumors 
containing an NF2 mutation 10,62-65. This difference could be explained by the involvement 
of other (epi)genetic changes that cause down-regulation of NF2 expression. Another reason 
could be the fact that the utilized mutation detection methods were not sensitive enough. 
A possible factor impairing the sensitivity of these analyses is contamination of tumor tissue 
with for instance tumor invading cells of the intratumoral infiltrate. This theory is supported 
by our findings regarding the presence of tumor infiltrating macrophages in vestibular 
schwannomas 66,67.
Epigenetic alterations are involved in the development of many tumors 71,72. Hypermethylation 
of CpG Islands in the promoter region leading to gene silencing is an important epigenetic 
mechanism causing tumor suppressor inactivation 73. Aberrant methylation of NF2 has been 
investigated in several studies. Kino et. al.74 analysed 23 vestibular schwannomas and 
demonstrated aberrant methylation of NF2 in 14 tumors, suggesting it as an alternative 
pathway of NF2 inactivation. Gonzalez-Gomez 75 et. al. reported hypermethylation of NF2 
in just 6 out of 31 sporadic schwannomas. An even lower percentage was reported by Kullar 
et al.68. They found aberrant methylation of NF2 in 4 out of 40 sporadic vestibular 
schwannomas. Finally Lee et. al.69 investigated 30 vestibular schwannomas and found no 
aberrant methylation at all. The results of these studies vary considerably and do not provide 
a sufficient explanation for the subpopulation of vestibular schwannomas lacking a proven 
NF2 mutation. 
Global gene expression profiling of sporadic vestibular schwannomas 
Global gene expression profiling experiments provide powerful methods to analyse the 
expression pattern of a large panel of genes. Welling et al. 76 were one of the first to perform 
a cDNA microarray analysis on vestibular schwannomas. They studied 7 tumors and 
identified several deregulated genes. Among the up-regulated genes were osteonectin 
(SPARC), an angiogenesis mediator, and RhoB GTPase, which is important in cell signaling. 
Among the down-regulated genes was LUCA-15 which is related to apoptosis. Ezrin, a 
relative of merlin, was also down-regulated in a majority of tumors. This studies’ main 
limitation was the small number of samples, making statistical analysis difficult.
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A microarray analysis by Cayé-Thomasen et al. 77 investigated 16 vestibular schwannomas 
and compared their gene expression pattern with 3 vestibular nerves. An interesting up-
regulated gene was platelet-derived growth factor D which is involved in cell cycle regulation. 
PTEN (phosphatase and tensin homolog deleted on chromosome 10), a tumor suppressor 
gene and major regulator of the PI3K/AKT pathway, was also up-regulated. The authors 
suggested PTEN up-regulation as compensatory for the lack of merlin inhibition. Comparison 
of the results of Cayé-Thomasen et al. and Welling et al. revealed an association related 
to SPARC. Welling et al found this gene to be up-regulated while the scavenger receptor 
stabilin-1, involved in SPARC degradation, was up-regulated in the analysis by Cayé-
Thomasen et al. Subsequently Aarhus et al. 59 demonstrated up-regulation of SPARC as 
well, emphasizing the role of this gene in vestibular schwannoma biology.
Another finding of Aarhus et al. was the down-regulation of tumor suppressor gene CAV1, 
suggesting that loss of CAV1 participates in vestibular schwannoma formation. Additionally 
they performed a network and pathway analysis which indicated the ERK pathway as the 
central core linking the differentially expressed genes.  
Coinciding results were reported in a microarray analysis by Torres-Martin et al. 70 They 
postulated that down regulation of CAV1 in schwannomas leads to deregulation of MET, a 
tyrosine kinase receptor involved in cellular mechanisms like proliferation, motility and 
migration. Table 2 provides an overview of these data. 
An important consideration when interpreting the results of these expression profiling studies 
is the issue of the control tissue. Most studies used peripheral nerve tissue. Peripheral 
nerves predominantly contain axons surrounded by Schwann cells whereas tumor tissue 
mainly consists of schwannoma cells. This proportional discrepancy in tissue type can 
cause non-tumor-related differential cDNA expression which may obscure the actual results. 
Table 1. NF2 mutations in sporadic vestibular schwannomas 
Author (ref.nr.) Year NF2 mutation rate
Irving et al. 58 1994 13 out of 85 (15%) 
Sainz et al.10 1994 17 out of 26 (65%) 
Welling et al. 56 1996 19 out of 29 (66%)
Jacoby et al. 57 1996 41 out of 49 (84%) 
Hadfield et al. 61 2010 65 out of 98 (66%) 
Aarhus et al. 59 2010 19 out of 25 (76%) 
Kullar et al. 68 2010 12 out of 40 (30%) 
Lee et al. 69 2012 16 out of 30 (53%) 
Lassaletta et al. 60 2013 25 out of 51 (49%)
Zhang et al.65 2013 50 out of 145 (35%)
Torres-Martin 70 2013 23 out of 31 (74%)
Epigenetic alterations of NF2 
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Angiogenesis and the role of the tumor microenvironment
Although vestibular schwannomas are relatively slow-growing neoplasms they still require 
angiogenesis to progress beyond a certain size 78. Multiple angiogenesis stimulating factors 
have been identified; the best established is vascular endothelial growth factor (VEGF). 
VEGF is expressed by vestibular schwannoma cells 79-82 and several studies have correlated 
the degree of VEGF expression with clinical parameters such as tumor growth 79,81, tumor 
volume 83 and microvessel-density 83. VEGF expression can be induced by hypoxia in 
response to the production of HIF-1alpha (Hypoxia inducible factor 1alpha) 84,85. Diensthuber 
et al. 86 studied HIF-1alpha in sporadic vestibular schwannomas and demonstrated a relation 
between HIF-1alpha expression and cell proliferation. Next to hypoxia there are other 
microenvironmental factors regulating angiogenesis and tumor progression. Moller et. al. 
investigated matrix metalloproteinase-9 (MMP-9), an enzyme involved in migration and 
invasion of endothelial cells during angiogenesis. They studied 37 sporadic vestibular 
schwannomas and demonstrated a correlation between MMP-9 expression and tumor 
growth 87. Inflammation is also capable of influencing tumor behavior. Macrophages form 
the major determinants of intratumoral inflammation. These so called tumor associated 
macrophages are associated with angiogenesis, cell growth and down-regulation of the 
immune response 88. We performed a study on 68 sporadic 89vestibular schwannomas and 
found a correlation between the expression of CD68 positive macrophages, tumor size and 
angiogenesis 66. In a subsequent study we were able to support the concept of inflammation 
mediated tumor progression by linking macrophage expression to tumor growth 67. The 
active role of inflammation in vestibular schwannomas is denoted by the presence of the 
enzyme COX-2. 90 COX-2 is expressed at sites of inflammation and effects angiogenesis 
91. Vestibular schwannomas with higher proliferation rates show higher COX-2 expression90. 
Vestibular schwannoma angiogenesis also seems to be stimulated by the down-regulation 
of the antiangiogenic factor semaphoring 3F (SEMA3F)7. A study by Wong et al.92 
Table 2. global gene expression 
Series (refnr.) Gene Function Regulation status 
Welling et.al. 76 SPARC angiogenesis up-regulated 
RhoB GTPase promotion of cellular functions  
related to cancerous cells 
up-regulated 
LUCA-15 apoptosis down-regulated 
Cayé-Thomassen et.al 77 PDGFD cell growth and division up-regulated 
PTEN tumor supressor up-regulated 
Stabilin-1 degradation of SPARC up-regulated 
Aarhus et.al. 59 SPARC angiongenesis up-regulated 
CAV1 tumor supressor down-regulated 
Torres-Martin et.al. 70 CAV1 tumor supressor down-regulated 
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demonstrated the ability of merlin to up-regulate SEMA3F through Rac1 thereby decreasing 
angiogenesis. All together these studies support the importance of angiogenesis in vestibular 
schwannoma development, making it an interesting target for pharmacotherapeutic 
treatment. 
Targeted therapy
As mentioned in previous paragraphs the increasing biological knowledge on vestibular 
schwannomas helps to identify targets for therapy. Next to angiogenesis other targets are 
emerging. Various components of the cell signalling pathways affected by merlin, like the 
receptor tyrosine kinases IGF1R, EGFR and PDGF, might also form targets for therapy. 
These growth factors are normally supressed by merlin but can be inhibited pharmacologically 
as well. 
Current research on targeted therapy for vestibular schwannomas primarily focuses on the 
neurofibrosis type 2 related tumors. This paragraph discusses the latest developments 
regarding these pharmacotherapeutic options.
The angiogenesis inhibiting drug bevacizumab is an anti-VEGF antibody approved by the 
U.S. Food and Drug Administration for the treatment of several types of cancer. Plotkin et 
al. 7 were the first to investigate the effect of bevacizumab in NF2 patients. They 
demonstrated tumor shrinkage and mild hearing improvement in 9 out of 10 subjects. 
Mautner et al. 5 reported similar results. The effect of anti-VEGF therapy was also confirmed 
by Wong et al. 6. They showed that angiogenesis inhibitors bevacizumab or vandetanib 
decreased vascularisation and growth rate of schwannoma xenografts in mice. Finally, a 
retrospective study on 31 NF2 patients demonstrated hearing improvement and tumor 
shrinkage with bevacizumab in more than 50% of the patients 93. It should be noted that 
sustainable tumor control requires long term treatment with bevacizumab 94. Because side 
effects of bevacizumab include hypertension, disrupted blood coagulation, embolism and 
kidney complications great caution should be exercised before starting therapy. 
Another way to inhibit angiogenesis is by blocking the platelet-derived growth factor (PDGF) 
pathway. Besides having a proangiogenic function PDGF serves as a mitogen for Schwann 
and schwannoma cells. Therefore PDGF inhibitors have a direct effect on the schwannoma 
cells themselves as well. A drug capable of inactivating this pathway is imatinib mesylate 
(Glivec) 37,95. The possibility that PDGF serves as a target for vestibular schwannoma 
treatment was first suggested by Altuna et al. 37,96. They demonstrated that vestibular 
schwannomas express the PDGF Receptor-β and showed the ability of imatinib to alter cell 
cycle distribution and induce apoptosis in the vestibular schwannoma cell line HEI193. They 
additionally demonstrated that imatinib inhibited cell proliferation in HEI193 and in primary 
vestibular schwannomas cells. Yener et al. 97 confirmed the growth inhibitory effect of imatinib. 
They conducted angiogenesis assays on vestibular schwannomas. Imatinib proved to be 
effective in reducing the angiogenic activity. Ammoun et al. 98 compared imatinib with the 
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more potent PDGFR receptor inhibitor nilotinib (Tasigna). They found nilotinib to effectively 
inhibit proliferation of vestibular schwannoma cells at concentrations 6-10 times lower than 
imatinib. Additionally they demonstrated that a combination of nilotinib with selumetinib 
(AZD6244), a MAPK kinase inhibitor, even further inhibited cell proliferation. 
Apart from antiangiogenic therapies other therapeutic agents have been tested. Lapatinib 
is a dual EGFR/ErbB2 inhibitor. In vitro studies have demonstrated that this drug achieves 
inhibition of cell proliferation in vestibular schwannoma cell cultures and it induces apoptosis 
in the HEI193 cell line 100,101. This effect was endorsed by a phase II trial testing volume and 
hearing responses in NF2 patients. Results showed ≥15% tumor volume decrease in 4 out 
of 17 patients. Hearing was monitored in 13 patients, 4 of which experienced an improvement 
in pure tone average of at least 10 dB 107. 
The recently developed histone deacetylase inhibitor AR42 capable of blocking the PI3K/
AKT pathway proved to be a potent growth inhibitor of schwannoma- and meningeoma 
cells 103. Targeting PDK1, which is a crucial activator of this pathway, can also inhibit AKT 
signalling in schwannoma cells 108 Yet another tyrosine kinase inhibitor tested for vestibular 
schwannoma therapy is erlotinib. It acts through HER-1/EGFR inhibition. Erlotinib showed 
to inhibit growth of vestibular schwannoma xenografts in nude mice 109. Subsequent tests 
on the efficacy of erlotinib in 11 vestibular schwannoma patients 99 showed no radiographic 
or hearing responses but some patients did experience prolonged stable disease.
FRAX597 is an inhibitor of PAK, the kinase responsible for the phosphorylation of merlin 
(Figure 3).  Licciulli et al. 104 found it to reduce proliferation in schwannoma cell lines and 
impair tumor development in an NF2 mouse model. Giovannini et al. showed that targeting 
the mTORC1 pathway with rapamycin (Sirolimus) leads to antagonization of tumorgenesis. 
This observation was made in in vitro as well as in vivo schwannoma models. They even 
seemed to induce tumor growth arrest in an NF2 patient 105 It should be noted that these 
observations are opposed by results of a trial describing no tumor resonse in 9 patients 
treated with mTOR inhibitor everolimus 102
Finally there is the remarkable observation that plain aspirin is also associated with halted 
growth of vestibular schwannomas106. It is suggested that the COX2 inhibiting effect of 
aspirin dampens the pathologic immune response and its tumour promoting stimuli resulting 
in halted tumor progression. Table 3 provides an overview of target therapy tested for 
vestibular schwannomas. 
Future prospects
To date a wide range of potential therapeutic targets for vestibular schwannoma treatment 
has been studied. Most drugs seem to induce an antiangiogenic or cytostatic response. An 
actual cytotoxic effect resulting in apoptosis has also been observed, for example with drugs 
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targeting EGFR and PDGF. By simultaneously targeting EGFR and ErbB2 actual tumour 
shrinkage could be accomplished in a number of NF2 patients. This outcome emphasizes 
the potential effect of combining different therapies. The ideal would be a therapeutic 
regimen of drugs tailored to the gene- or protein expression pattern within each individual 
tumour. Such an approach would require analysis of tumour tissue, which is virtually 
impossible in non-surgically treated patients, but could be applied in a subgroup of patients 
suffering from tumour recurrence after surgery. The knowledge of having a good treatment 
alternative after surgery may also lessen the need for radical tumour extirpation, allowing 
more limited surgery with less morbidity.
Combining drugs with radiotherapy, a treatment approach already applied for different types 
of cancer, is another strategy worth considering. A recent study combing a c-Jun N-terminal 
kinase (JNK) inhibitor with gamma radiation110 shows that the combination of these 
therapeutic strategies can be successful in vestibular schwannomas as well. Altogether 
these emerging therapeutic targets will help to further reduce the need for surgical 
intervention.
Table 3. Summary of research on targeted therapy 
Drug Target Author (ref. nr.) Main results 
Bevacizumab VEGF Plotkin et al. 7 Tumor shrinkage and mild hearing improvement in 9 out 
of 10 patients.
Plotkin et al.93 Tumor shrinkage in >50% of 31 analysed patients 
Mautner et al. 5 >40% tumor shrinkage in 2 out of 2 patients. 
Wong et al. 6 Mouse model showing decrease of tumor vasculature 
after bevacizumab. Tumor growth decreased and the 
survival of treated mice extended by 50%. 
Erlotinib EGFR Plotkin et al.99 No radiographic or hearing response in 11 patients.  
Imatinib PDGF Altuna et al. 96 In vitro study demonstrating apoptosis and inhibition of 
cell proliferation
Yener et al. 97 In vitro study demonstrating reduction of angiogenesis in 
tissue specimens of NF-2 related as well as sporadic 
tumors. 
Lapatinib EGFR/ErbB2 Ahmad et al. 100 In vitro study demonstrating decrease of cell growth and 
proliferation in vestibular schwannoma cell cultures. 
Ammoun et al. 101 In vitro study demonstrating decreased proliferation in a 
human schwannoma model 
Karajannis et al. 102 Phase II trial demonstrating hearing an volume responses 
in lapatinib treated NF2 patients 
AR42 PI3K/AKT Bush et.al.103 Growth inhibition of schwannoma cells 
FRAX597 PAK Licciulli et al.104 In vitro study displaying reduced schwannoma cell 
proliferation and an in vivo experiment indicating 
impairment of tumor development. 
Rapamycin mTORC1 Giovannini105 Tumor growth arrest in one NF2 patient




During the past years there has been a tremendous increase in knowledge of vestibular 
schwannoma biology. The mechanisms through which merlin carries out its functions are 
gradually elucidated. This process goes hand in hand with the identification of novel 
therapeutic targets. Up till now targeting angiogenesis seems the most successful 
pharmacological strategy but additional therapeutic options are emerging. Other tumor 
biological issues that deserve to be part of future research are the processes responsible 
for the variable growth pattern of these tumors, the discrepancies regarding the occurrence 
of (epi) genetic changes to NF2, and the potential involvement of additional genes and 
signalling pathways.
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Abstract
Objective: identification of clinicopathologic factors related to vestibular schwannoma 
progression.
Background: vestibular schwannomas show a large variation in growth rate, making 
prediction and anticipation of tumor growth difficult. More accurate prediction of clinical 
behaviour requires better understanding of tumor biological factors influencing tumor 
progression. 
Methods: biological processes like intratumoral haemorrhage, cell proliferation, microvessel 
density, and inflammation were analysed in order to determine their role in vestibular 
schwannoma development. Tumor specimens of 67 patients surgically treated for a 
histologically proven unilateral vestibular schwannoma were studied. Preoperative magnetic 
resonance imaging (MRI) scans were used to determine tumor size and to classify tumors 
as homogeneous, inhomogeneous, and cystic. Immunohistochemical studies evaluated 
cell proliferation (histone H3 and Ki-67), microvessel density (CD31), and inflammation 
(CD45 and CD68). Intratumoral haemorrhage was assessed by hemosiderin deposition. 
The expression patterns of these markers were compared with tumor size, tumor growth 
index, MRI appearance, patients’ age, and duration of symptoms. 
Results: no relation between cell proliferation and clinical signs of tumor volume increase 
or MRI appearance was found. Intratumoral hemosiderin, microvessel density, and 
inflammation were significantly positively correlated with tumor size and the tumor growth 
index. Cystic and inhomogeneous tumors showed significantly more hemosiderin deposition 
than homogeneous tumors. The microvessel density was significantly higher in tumors with 
a high number of CD68-positive cells. 
Conclusion: the volume increase of vestibular schwannomas is not based on cell 
proliferation alone. Factors like intratumoral bleeding, (neo)vascularization, and intensity 
of the inflammatory reaction also influence tumor volume.
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Introduction
Vestibular schwannomas (acoustic neuromas) are benign tumors originating from the 
myelin-forming Schwann cells of the vestibular branch of the eighth cranial nerve in the 
internal auditory canal or cerebellopontine angle. Clinically, these tumors grow slowly and 
progressively, eventually causing brainstem compression.
One of the problems in the treatment of these tumors is the large variation in the evolution 
of increase in volume in time. Why this is so variable remains largely unknown, but clinically, 
this makes prediction and anticipation of the evolution of symptoms difficult. Current 
therapeutic management is mainly based on symptoms and radiological assessment. 
Unfortunately, these indicators do not always correlate with actual tumor volume increase. 
More accurate prediction of tumor expansion rate could lead to more balanced decision-
making regarding therapeutic actions when a vestibular schwannoma is diagnosed.
Accurate assessment of potential tumor volume increase requires better understanding of 
tumor biological (growth) factors and concurrent pathological events like cyst formation. To 
gain more insight in the role of these factors, we assessed the relationships between 
(immuno)histopathological markers, radiological observations on tumor appearance, and 
clinical growth of vestibular schwannomas.
One way for tumors to expand is by cell proliferation. A well-known proliferation marker is 
the Ki-67 antigen 1,2 , which is present during all phases of the cell cycle but is absent in 
noncycling cells. A less known indicator for proliferation is the phosphorylated histone H3 
protein, which is expressed during mitosis 3-5. Both these markers were included in this 
study. In addition to proliferation, we investigated to what extent intratumoral haemorrhage, 
microvessel density, and the degree of inflammation are involved in tumor expansion. To 
quantify intratumoral haemorrhage, hemosiderin (i.e., iron) deposition was evaluated. The 
endothelial marker CD31 was used to measure microvessel density, and the degree of 
inflammation was determined by quantifying the number of leukocytes and macrophages 
through the expression of the markers CD45 and CD68, respectively.
Material and methods
Patients
From the vestibular schwannoma database at the Leiden University Medical Center, a total 
of 67 patients (26 males and 41 females) were identified. They involved a group of patients 
surgically treated for a histologically proven vestibular schwannoma from January 2000 to 
November 2005. The main criteria for surgical treatment were clinical symptoms (e.g., 
progressive or debilitating vertigo and hearing loss) and tumor size, both initial as well as 
in terms of progression over time. Patients’ personal preference was also of great importance 
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in deciding if and when to apply treatment. Only cases of unilateral sporadic schwannomas 
were selected, patients diagnosed with NF2 were excluded.
Tumor measurement
Information on radiological data was obtained from radiology records which are all composed 
according to specific clinical and scientific incentives. These standardized reports include 
measurement of the greatest tumor diameter according to the guidelines of the American 
Academy of Otolaryngology Head and Neck Surgery 6. Additionally, the reports comprise 
evaluation of tumor density based on gadolinium-enhanced T1-weighted as well as T2-
weighted scans. Depending on the presence of microcystic and or macrocystic components, 
tumors were classified as homogeneous, inhomogeneous, or cystic. All patient data were 
prospectively discussed at a multidisciplinary conference attended by representatives of 
the neurosurgery, radiology, radiotherapy, pathology, and otolaryngology department. 
Clinical and radiological data were cross checked before being entered in the vestibular 
schwannoma database (for the exact patient characteristics, including figures illustrating 
cystic, inhomogeneous, and homogeneous tumors, see Electronic supplementary material 
Figures 1, 2, and 3).
Immunohistochemistry
The immunohistochemical tests were conducted at the Department of Pathology of the 
Leiden University Medical Center. The tests were conducted on specimens preserved in 
formalin and stored in paraffin. All assessments were performed on tissue sections obtained 
from one single tumor block per tumor sample. Immunohistochemical reactions were 
performed according to standard laboratory methods 7. In brief, heat-induced antigen 
retrieval was performed using microwave treatment of all sections after dewaxing and 
rehydration, followed by blocking of endogenous peroxidase with 3 % H2O2 in methanol. 
Incubation with primary antibodies was overnight (for sources, working dilutions, and positive 
controls used, see Table 1). Subsequently, sections were incubated with poly-HRP-
antimouse/rabbit/rat conjugate. Visualization was carried out with a H2O2–diaminobenzidine 
solution. All washing procedures were performed in phosphate-buffered saline. Slides were 
counterstained with hematoxylin. In addition to the immunohistochemical stains, hemosiderin 
staining was performed.
Microscopic analysis
In order to obtain an overall impression of the staining pattern of each marker, all sections 
were first evaluated using a × 10 objective lens. Hemosiderin, CD45, and CD68 displayed 
an irregular/patchy staining pattern, making computer-assisted analysis less reliable. For 
this reason, further analysis of these markers was performed manually in a semiquantitative 
score. Per specimen, 10 randomly chosen fields of view (FOV) were evaluated at a × 40 
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objective lens. Scoring was independently assessed by two authors. The degree of staining 
was scored as follows: 0, absent; 1, mild; and 2, strong.
Staining for Ki67 and histone H3 showed a more homogeneous distribution, permitting the 
application of a computer-based image analysis method in order to determine the index of 
proliferation. In brief, of each specimen, five randomly chosen digital snapshots were taken. 
Positively stained nuclei were identified through spectrometry using a Leica DM4000B 
microscope fitted with a CRI Nuance spectral analyser (Cambridge Research and 
Instrumentation, Inc., Woburn, MA, USA). Using Mirax software (Zeiss, Germany) and 
ImageJ (National Institutes of Health, Bethesda, MD, USA), the number of pixels 
representing positively stained nuclei was determined, as well as the number of pixels 
representing the total nuclear area in one FOV. The index of proliferation was calculated 
by dividing the number of immunopositive pixels by the number of pixels representing the 
total nuclear area. The mean value of the five snapshots was used for statistical analysis.
Microvessel density was determined with the Chalkley point overlap morphometric 
technique, which allows for rapid analysis with a relatively low interobserver variability 8. 
This method has been described in detail 9,10. In brief, CD31 stained sections were scanned 
for hot spots of high vascular density. Using an ocular grid with 25 random points, 
microvessel density was scored in these hot spots with a × 20 objective lens. The grid was 
oriented to permit the maximum number of points to hit the stained microvessels (Figure 
1). The Chalkley count was the mean of the maximum number of points hitting a microvessel 
in three hot spots per tumor specimen.
Tumor growth index
Accurate measurement of tumor growth depends on serial magnetic resonance imaging 
(MRI) scanning over a longer period of time. Because only six patients in our selection 
underwent serial MRI scanning prior to surgery, this method of growth assessment could 
not be used in our study. We used the tumor growth index as a surrogate parameter. This 
index has been described earlier regarding vestibular schwannoma growth 11,12. Its basic 
assumption is that the age of onset of the tumor varies randomly. The tumor growth index 
is calculated by dividing the maximal tumor diameter by the age of the patient.
Table 1. Antibody concentrations and positive control tissues used 
Antibody Supplier Concentration Positive control
Ki-67 DAKO 1:800 Tonsil
Histone H3 Comproscientific 1:3,200 Tonsil
CD31 DAKO 1:150 Tonsil
CD45 DAKO 1:4,000 Tonsil




For evaluation of the relationships between the tumor biological markers and parameters of 
clinical growth, the Spearman rank correlation test was used. The difference in hemosiderin 
deposition between cystic and inhomogeneous tumors versus homogeneous tumors was 
determined by the chi-square test. Tumor size of cystic and inhomogeneous tumors versus 
homogeneous tumors was compared with the unpaired t test. The relation between 
microvessel density and CD68 expression was evaluated using the one-way analysis of 
variance (ANOVA) and Scheffe test. For all statistical tests, p < 0.05 was considered as 
significant. All calculations were performed using SPSS Inc. software, version 17.0.
Results
A total of 67 patients (age: range, 15–72 years; mean, 49.04 ± 14.06 years) was studied. 
Maximum tumor diameter varied between 5 and 50 mm (mean, 24.03 ± 11.52 mm) and the 
Figure 1. Examples of Chalkley counts in vascular hotspots, 
specimen a and b score 10 and 6, respectively (original 
magnification × 200)
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tumor growth index (which does not represent actual increase in size but a parameter for 
tumor growth rate) varied between 0.07 and 2.11 mm/year (mean, 0.56 ± 0.40 mm/year)
The mean value of the Ki-67 index in this studied group was 0.6 % (range, 0.1–1.8 %). For 
the histone H3 index, the mean value was 3.9 % (range, 0.4–15.5 %). No significant 
correlation was found between the Ki-67 or histone H3 index and maximal tumor diameter, 
tumor growth index, and radiologically measured tumor growth.
The number and distribution of hemosiderin-, CD45-, and CD68-positive cells in the tissue 
sections were very heterogeneous. Some specimens showed no staining at all, yet other 
specimens showed a substantial number of positive cells (Figure 2). The mean Chalkley 
count was 9.59 (range, 3.3–23.0; SD, 3.70). The Spearman rank correlation test demonstrated 
several significant positive correlations between these markers (Table 2, for the corresponding 
scattergrams, see Electronic supplementary material Figures 4, 5, and 6).
The number of hemosiderin-positive cells correlated with tumor size (p < 0.001; r = 0.39) 
and tumor growth index (p < 0.006; r = 0.33). CD45 expression correlated with tumor size 
(p < 0.006; r = 0.33) and tumor growth index (p < 0.002; r = 0.38), and CD68 expression also 
correlated with tumor size (p < 0.0001; r = 0.46) and tumor growth index (p < 0.0001, r = 0.48).
Figure 2. a Proliferating cells (Ki-67/histone H3), b intratumoral bleeding (hemosiderin), c high microvessel density 
(CD31), and d intratumoral inflammation (CD45/CD68) (original magnification × 400)
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The Chalkley count demonstrated a positive correlation with tumor size (p < 0.001; r = 0.40) 
and tumor growth index (p < 0,002; r = 0.37). Furthermore, the Chalkley count showed a 
significant correlation with the number of hemosiderin-positive cells (p < 0.003; r = 0.36), 
CD45-positive cells (p < 0.021 r = 0.28), and CD68-positive cells (p < 0.0001; r = 0.47). A 
one-way ANOVA and a Scheffe test confirmed the positive relation between the number of 
CD68-positive cells and microvessel density. Tumors with a high number of CD68-positive 
cells displayed a significantly higher microvascular density than tumors with low or no 
CD68-positive cells (Figure 3).
In 61 patients, the tumors were morphologically classified based on their MRI appearance. 
Twenty-four tumors were classified as homogeneous, 8 as inhomogeneous, and 29 as 
cystic. Cystic and inhomogeneous tumors were significantly larger than homogeneous 
tumors (Table 3). Cystic and inhomogeneous tumors also displayed a significantly higher 
number of hemosiderin-positive cells than homogeneous tumors (Table 3). No statistically 
significant correlations or differences were observed when patient age or duration of 
symptoms was taken into account.
Figure 3. Relation between CD68 expression and microvessel density. The mean Chalkley count is significantly 
higher in tumors with strong CD68 expression. Asterisk denotes statistical differences calculated with the Scheffe 
test.
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Discussion
To gain more insight into the mechanisms responsible for volume increase of vestibular 
schwannomas, possible correlations between histopathological markers and radiological 
and clinical characteristics of vestibular schwannomas were investigated. For studying the 
growth rate of a tumor, serial radiological observation is the preferred method. As most 
patients in this study were operated on shortly after diagnosis, in the majority of cases, only 
one preoperative MRI scan was obtained, which excluded this approach. As a surrogate, 
we used the growth index, which is only a rough estimate of the rate of tumor volume 
increase but allowed us to include a larger number of patients in the study.
To evaluate the role of proliferative activity in the volume increase of vestibular schwannomas, 
the cell cycle markers Ki-67 and histone H3 were used. Ki-67 as a parameter of growth of 
vestibular schwannomas has been studied by Niemczyk et al. 2, who compared clinically 
stable vestibular schwannomas with clinically growing cases. They found a significant 
difference in Ki-67 labeling index between the two groups. The mean labeling index in the 
growing tumors was 3.17 % compared to 1.11 % in the stable tumors. Overall, the Ki-67 
index ranged from 0.22 to 5 %, with an average of 1.86 %. Gomez et al. 13 also investigated 
cell proliferation in vestibular schwannomas, but did not find a significant correlation between 
tumor growth and Ki-67 labeling index, which ranged from 0.2 to 2.2 %. We conclude that 
the labeling index of Ki-67 in our study (ranging from 0.1 to 1.8 %, with a mean of 0.6 %) 
is comparable with earlier published data.
Table 2. Spearman’s correlation test for pathological markers and clinical characteristics 
Ki-67 Histone H3 CD45 CD68 Siderina MVD
Size Correlation coefficient 0.129 0.326 0.333** 0.457** 0.392** 0.397**
Significance (two-tailed) 0.301 0.120 0.006 0.000 0.001 0.001
TGI Correlation coefficient 0.091 0.275 0.375** 0.482** 0.330** 0.373**
Significance (two-tailed) 0.466 0.243 0.002 0.000 0.006 0.002
MVD Correlation coefficient 0.140 0.240 0.281* 0.472** 0.363** -
Significance (two-tailed) 0.261 0.102 0.021 0.000 0.003 -
TGI tumor growth index, MVD microvessel density, aHemosiderin
Table 3. MRI appearance compared by hemosiderin deposition and size 
Hemosiderin deposition a Size  b
MRI c absent mild strong x 2 df p mean ± SD p
Homogeneous 15 7 2 8.67 2 <0.013 13.46 ± 8.44 < 0.0001
Inhomogeneous/cystic 10 15 12 30.46 ± 8.43
a chi square test;  b independent t-test ; c magnetic resonance imaging.
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Histone H3 as a proliferation marker has not been studied in vestibular schwannomas 
before. We did not find a correlation between the histone H3 labeling index and the tumor 
growth index. Taken together, our data and those from the literature indicate that cell 
proliferation is not a decisive factor in the expansion of vestibular schwannomas.
Degenerative changes such as cysts may contribute to tumor volume increase. Reports 
on the incidence of cyst formation in vestibular schwannomas vary between 5.7 and 48 %, 
with more recent studies indicating incidences of approximately 10 % 14-17. Cystic tumors 
can display a relatively rapid increase in volume and generally become larger than noncystic 
tumors 18. This also applies to our case series, the cystic and inhomogeneous tumors being 
significantly larger than the homogeneous tumors. The mechanisms responsible for cyst 
formation in vestibular schwannomas remain unclear. Gomez et al 13 . demonstrated a 
significant correlation between hemosiderin deposition, tumor size, and tumor heterogeneity 
and suggested that hemosiderin resorption might induce cyst formation. The same 
suggestion is made by Park et al. 19. Our results are in line with these studies. We found 
significantly more hemosiderin deposition in cystic and inhomogeneous tumors compared 
to homogeneous tumors. The significant correlations between hemosiderin deposition and 
tumor size and tumor growth index also support this notion.
These results may offer a clue in the search for markers of tumor volume increase. Both 
cysts and iron deposition are radiologically demonstrable and might, therefore, constitute 
clinically applicable markers. A radiological study on pituitary macroadenomas by Stadlbauer 
et al. 20 described a significant difference in spectral signals measured in hemorrhagic versus 
nonhemorrhagic tumors. The authors suggested that the paramagnetic effect of hemosiderin 
deposition in hemorrhagic tumors on the MR images might provide an explanation. Using 
this approach to study iron deposition and cyst formation in vestibular schwannomas might 
establish a causal relationship between intratumoral hemorrhage and cyst formation.
Although vestibular schwannomas are relatively slow-growing neoplasms, they depend for 
further growth on a functional vascular system, as any other tumor 21. The positive correlation 
between microvessel density and tumor size and tumor growth index we found is consistent 
with other published data 22,23. These findings suggest that angiogenesis may be important 
for the volume increase of vestibular schwannomas. Determining the degree of 
vascularization of vestibular schwannomas might also be possible using MRI diffusion or 
perfusion techniques 24-26. Further research into this hypothesis could lead to another 
clinically applicable marker of tumor volume increase. These results also suggest that 
antiangiogenesis therapy might contribute to controlling tumor growth.
The degree of inflammation measured by the expression of CD68 and CD45 showed a 
positive significant correlation with tumor size and tumor growth index. Similar correlations 
have not been reported in the literature yet. In a study performed by Brieger el al. 27 on 
angiogenic growth factors in vestibular schwannomas, tumor-infiltrating CD68-positive 
lymphocytes were not detected. Labit et al. 28 only found a correlation between the number 
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of CD45-positive cells and the duration of symptoms. The mechanism responsible for or 
the significance of an inflammatory reaction in vestibular schwannomas has not been 
elucidated as yet. Studies on breast cancer have addressed the role of the inflammatory 
microenvironment in tumor progression 29-35. It has been proposed that inflammation which 
triggers angiogenesis might contribute to tumor progression. Macrophage activity is a major 
determinant of the intratumoral inflammatory milieu but other components of the inflammatory 
infiltrate also seem to modulate tumor behaviour 36. The significant associations between 
the degree of inflammation (i.e., CD45 and CD68) and tumor size and tumor growth index 
and, in addition, the significant increase of microvessel density in tumors with a higher 
number of CD68-positive cells (Figure 3) suggest that similar processes take place in 
vestibular schwannomas. Several approaches targeting macrophage activity are currently 
under investigation 37,38, making additional research of the inflammatory process in vestibular 
schwannomas even more interesting. The first step would be further typing of inflammatory 
cells present in vestibular schwannomas. Furthermore, their activation state and relationship 
with angiogenic growth factors should be examined.
The results of this study indicate that tumor volume increase of vestibular schwannomas 
is not based on cell proliferation alone. Contributing factors are intratumoral hemorrhage, 
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CHAPTER 4
Abstract
Objective: determine whether the most frequent mutations affecting the MAPK/ERK 
pathway contribute to vestibular schwannoma progression 
Background: sporadic vestibular schwannomas are benign tumors originating from the 
Schwann cells of the vestibular portion of the eigth cranial nerve. An important clinical 
hallmark of these tumors is their variable growth rate. Investigating vestibular schwannoma 
biology can help to clarify this variable growth rate and may offer targets for therapeutic 
treatment. A recent mutation analysis on sporadic non head and neck schwannomas 
detected BRAF mutations in around 20 % of tumors. BRAF is part of the MAPK/ERK 
pathway. MAPK/ERK activation is associated with uncontrolled cell growth. Mutated BRAF 
can function as a target to inhibit this pathway. Mutations in BRAF and other members of 
the MAPK/ERK pathway have not been investigated in sporadic vestibular schwannomas 
before. 
Methods: Tumor specimens of 48 patients surgically treated for a sporadic vestibular 
schwannoma were analyzed. An allele specific quantitative real-time PCR assay was 
performed to detect the thirteen most frequent mutations affecting BRAF, EGFR, PIK3CA, 
and KRAS. Radiologically measured tumor growth was included in the analysis to identify 
potential relationships between these mutations and tumor progression. 
Results: No activating hotspot mutations in BRAF, EGFR, PIK3CA or KRAS were detected 
in the investigated vestibular schwannomas.  
Conclusion: the thirteen most frequent mutations affecting BRAF, EGFR, PIK3CA and 
KRAS are not involved in sporadic vestibular schwannoma development. These results are 
in contrast to the recent detection of these BRAF mutations in non-head and neck 
schwannomas and are as such no explanation of the clinically observed  variable growth 
pattern.
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Introduction
Sporadic vestibular schwannomas are benign tumors recapitulating the differentiation 
repertoire of the myelin-forming Schwann cells of the vestibular branch of the eighth cranial 
nerve in the internal auditory canal or the cerebellopontine angle. These tumors grow 
clinically slowly and progressively, extending into the cerebellopontine angle ultimately 
causing brainstem compression.
Therapeutic management of these tumors can be divided into three different strategies i.e. 
surgical removal, stereotactic radiotherapy or serial radiological observation, also known 
as the wait & scan policy. So far, unlike neurofibromatosis type 2-related tumors1, sporadic 
vestibular schwannomas are not pharmacotherapeutically treated. One of the clinical 
problems regarding vestibular schwannoma therapy is the large variability in growth rate 
these tumors can display. More understanding of this variable growth rate would be of great 
benefit when determining the most suitable therapeutic approach. This requires more insight 
into tumor biological factors affecting vestibular schwannoma progression. Studying the 
biology of the vestibular schwannoma not only contributes to a better understanding of its 
growth pattern, it may also help to identify potential therapeutic targets.
To date the tumor biology of sporadic vestibular schwannomas is poorly understood. An 
important factor in the development of schwannomas in general is loss of function of NF2 
(neurofibromin 2), which acts as a tumor suppressor gene2-5. Inactivation of the NF2 gene 
has been described in both neurofibromatosis type 2-related as well as sporadic vestibular 
schwannomas6-9. Reports regarding the sporadic tumors described NF2 mutations in a 
majority of cases 6-11. Nevertheless a significant proportion of sporadic vestibular 
schwannomas do not seem to harbour a proven NF2 mutation. Studies investigating the 
NF2 gene product in schwannomas, both at RNA- as well as protein level, demonstrated 
absent or decreased expression of NF2 gene products in a higher percentage of tumors 
then expected with regard to the percentage of tumors containing a proven NF2 mutation 
9,12-14. These findings suggest that in addition to mutational changes of NF2 other 
mechanisms are implicated in deregulating NF2 gene products. A study by Kino et. al.15 
demonstrated aberrant methylation of NF2 in 14 out of 23 schwannomas, both NF2-
related(n=3) as well as sporadic(n=20). A more recent study by Kullar et. al. 16 also 
investigated the role of methylation in vestibular schwannomas. They reported aberrant 
methylation of NF2 in only 10% of the investigated samples. In summary, quite some 
discrepancies between reports on the incidence of NF2 mutations, loss of NF2 gene product 
and epigenetic aberrations of NF2 exist. The combination of these discrepancies and the 
fact that no associations between aberrant NF2 expression and tumor growth have been 
demonstrated, leads to the impression that next to loss of function of NF2 other mechanisms 
are implicated in vestibular schwannoma development. 
A recent finding supporting this suggestion was reported by Serrano et al. 17 They identified 
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the presence of BRAFv600E mutations in a number of sporadic non head and neck 
schwannomas. The presence of BRAF mutations in schwannomas has been investigated 
before. Schindler et al. 18 investigated BRAFv600E mutations in 1320 nervous system tumors, 
including 14 schwannomas. None of these schwannomas contained the BRAFv600E mutation. 
Among the tumors that did harbour BRAF mutations were WHO grade II pleomorphic 
xanthoastrocytomas (42/64; 66%), pleomorphic xanthoastrocytomas with anaplasia 
(15/23;65%), WHO grade I gangliogliomas (14/77; 18%), WHO grade III anaplastic 
gangliogliomas (3/6) and pilocytic astrocytomas (9/97;9%). Alterations of BRAF in pilocytic 
astrocytomas have been described in other reports as well 19,20; Additioinal tumors of glial 
origin associated with BRAF mutations are glioblastomas 21 and oligodendroglial tumors 22, 
in both cases mutations occurred at low frequency. A relatively recent study on malignant 
peripheral nerve sheath tumors (MPNST) screened for multiple gene mutations including 
BRAF, PIK3CA and RAS 23. No BRAF or PIK3CA mutations could be identified but 2 out of 
11 sporadic MPNSTs contained mutations to the RAS gene. 
Both NF2 24-28 as well as BRAF 29 are known to be involved in the regulation of the MAPK/
ERK pathway (Figure 1). The MAPK/ERK pathway consists of a cascade of tyrosine kinase 
proteins that mediate cellular responses like cell division, differentiation and survival30,31. 
An estimated 30% of all human cancers harbour mutations related to this pathway 32 with 
mutations of  the BRAF gene being the most frequent29. A relatively recent global gene 
expression profile analysis performed by Aarhus et. al. 6 subscribes the role of this pathway 
in the pathogenesis of sporadic vestibular schwannomas. The fact that mutated BRAF and 
other members of the MAPK/ERK pathway form potential targets for pharmacological 
treatment29,33 emphasizes the relevance of investigating their involvement in vestibular 
schwannoma development. 
The goal of this study was to investigate the hypothesis that mutations affecting the MAPK/
ERK pathway, BRAFv600E in particular, play a role in the development of sporadic vestibular 
schwannomas and may even account for the subgroup of tumors exhibiting rapid tumor 
growth. 
In order to test this hypothesis we have conducted an allele specific quantitative real-time 
PCR assay with hydrolysis probes for the most frequent activating mutations related to 
MAPK/ERK pathway activation. The results of this mutation analysis were compared with 
clinical parameters such as tumor size and tumor growth rate.
Materials and Methods
Patient selection
From the vestibular schwannoma database at the Leiden University Medical Center material 
of a total of 48 out of 315 patients, operated between January 2005 and July 2011, was 
59
Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with vestibular schwannomas
4
selected. The selection consisted of patients surgically treated for a histologically proven 
primary sporadic vestibular schwannoma. Patients with a tumor exceeding 20 mm in 
diameter were operated in cooperation with the Department of Neurosurgery; no patients 
diagnosed with neurofibromatosis type 2 were included. Decision for surgical treatment 
was based on clinical symptoms (e.g. tinnitus, vertigo, hearing loss, increased cerebrospinal 
pressure and tumor size), radiologically observed tumor growth and patients’ personal 
preference.
We selected two different patient groups based on first clinical presentation. Group 1 
consisted of 30 consecutive patients with tumors smaller than 20 mm in diameter at first 
diagnosis. These patients initially enrolled into the wait and scan protocol. Surgery was 
performed only after tumor growth was observed during radiological follow up. Tumor growth 
rate was determined by comparing the maximal tumor diameter measured on two sequential 
MRI scans and is expressed in millimetres per year34. Because only patients with tumors 
of small- to moderate size were monitored over time, few patients with larger tumors were 
present in this first group. In order to study a patient cohort representing the entire spectrum 
of tumor sizes we added a second group of patients to our selection. Group 2 consisted of 
Figure 1. NF2 involvement in the MAPK/ERK pathway. NF2 becomes active through dephosphorylation. 
Dephosphorylated NF2 binds to a transmembrane receptor (TMR). NF2 then blocks the activation of Ras and Rac 
thereby inhibiting phosphorylation of Raf and MEK by PAK. NF2 also inhibits signaling from constitutively active RAS. 
(Cell signaling model as adopted from Morrison H. et al Cancer Res 2007;67:520-527)
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18 consecutive patients with large tumors, exceeding 30 mm in size at initial diagnoses. 
Because patients with large tumors are operated shortly after diagnosis, no radiological 
follow up on tumor growth rate is available for these patients. 
All tumor samples were handled in a coded fashion and all procedures were performed 
according to the ethical guidelines of the Code for Proper Secondary Use of Human Tissue 
in The Netherlands (Dutch Federation of Medical Scientific Societies). 
DNA isolation
DNA was extracted from formalin fixed paraffin embedded tumor blocks. To ensure the 
tumor samples contained sufficient amounts of tumor cells (> 70%) H&E-stained slides of 
all samples were evaluated on percentage of tumor cells in relation to non-neoplastic cells. 
In one case microdissection was required in order to obtain an adequate percentage of 
tumor cells. DNA was extracted from 10 μm sections of paraffin-embedded tissue and 
subsequently purified using a NucleoSpin® Tissue Kit (Macherey-Nagel, Düren, Germany). 
For DNA quantification a UV/VIS spectrometry analysis with a NanoDrop ND-1000 
spectrometer (Thermo scientific®, New York, New York) was performed. 
BRAF, EGFR, PIK3CA and KRAS mutation analysis
Exact details regarding the allele specific quantitative real-time PCR (qPCR) with hydrolysis 
probes (Applied Biosystems, Nieuwerkerk a/d IJsel, NL) that was conducted have been 
described before35. In short, the assay contained mutation specific hydrolysis probes for 
the detection of one BRAF, two EGFR, three PIK3CA and seven KRAS mutations (table 
1.). The BRAFv600E mutation included in this assay accounts for more than 90% of all BRAF 
mutations described in human cancer 36. The deletion of exon 19 and the point mutation in 
exon 21 at nucleotide 2573 of chromosome 7 account for approximately 90% of all mutations 
affecting EGFR 37. For KRAS 95% of all activating mutations are located in exon 1 (codons 
12 and 13) 38. The hotspot mutations of PIK3CA included in this analysis cover approximately 
80% of all mutations to this gene 39. 
All qPCR reactions were performed on a sealed LightCycler 480 multiwell Plate 384 (Roche 
Applied Science) in a LightCycler 480 Multiwell system (Roche diagnostics). For quality 
assessment the quantification cycle (Cq) was taken into account. Samples with Cq values 
exceeding 35 in the wild-type channel were rejected and excluded from further analysis. 
The endpoint fluorescence ratio Rm/Rwt was calculated to determine the presence or absence 
of a mutation. In case the Rm/Rwt ratio exceeded 0.7 a sample was considered positive for 
that specific mutation. An Rm/Rwt ratio smaller than 0.3 indicated the mutation was absent. 
Allele specific quantitative real-time PCR is a reliable and sensitive technique for the detection 
of mutations in BRAF, EGFR, PIK3CA and KRAS and has been validated in several studies 
investigating different types of tumors 35,40-45. This technique is also part of the routine mutation 
detection protocol deployed by the Molecular Diagnostics department in our hospital. 
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Results 
A total of 48 patients, 21 (44%) male and 27 (56%) female were studied. Patient age ranged 
from 21 to 81 years with an average of 53.2 (SD ± 11.9) years. In patient group 1 tumor 
size varied from 7 to 49 mm (mean 16.4 ± 9.8) and tumor growth rate varied from -1.3 to 
33.9 millimetres per year (mean 4.1 ± 6.1). Tumor size in patient group 2 varied from 30 to 
46 millimetres (mean 36.3 ± 5.3) Tumor size in the total patient selection varied from 7 to 
49 millimetres (mean 23.8 ± 12.8). As expected, tumor size in group 2 was significantly 
larger than tumor size in group 1. No other significant differences existed between the two 
groups. Exact details on statistical analysis and patient characteristics of clinical data are 
listed in table 2 and table 3 respectively. 
BRAF, EGFR, PIK3CA and KRAS mutation analysis
In none of the 48 investigated patients mutations affecting BRAF, EGFR, PIK3CA or KRAS 
were detected (see Figure 2 for an example of the qPCR results). All assays for BRAF, 
PIK3CA and KRAS gave Cq values <35. In four cases the Cq values of the EGFR assay 
exceeded 35 making interpretation of the endpoint fluorescence ratio for these samples 
less reliable, however indications for the presence of a mutation in these cases were 
unlikely.
Table 1. analyzed mutations 
















Table 2. statistical analysis of clinical data 
Clinical parameter Total Group 1 Group 2 P
age, year 53,2 ± 11,9 55,4 ± 11,2 49,3 ± 12,2 0,85†
female, % 56 56 56 0,94‡
size 23,8 ±  12,8 16,4 ± 9,8 36,3 ± 5,3 <0.00001†
growth, mm/year - 4,1 ± 6,1 - -
P: † t-test and ‡ chi-squared; ± indicate SD
Table 3a. patient characteristics and qPCR results of smaller tumors 
Sample Sex Age (yr) Size (mm) Growth
mm/yr
KRAS EGFR BRAF PIK3CA
Group 1 
L3716 M 69 17,6 -1,3 WT WT WT WT
L3717 F 67 12,9 2,7 WT WT WT WT
L3718 M 46 9,9 3,5 WT WT WT WT
L3719 F 60 11,6 2,1 WT WT WT WT
L3720 M 48 17,3 0,6 WT WT WT WT
L3721 M 60 6,8 0,5 WT WT WT WT
L3722 M 53 12,7 3,4 WT WT WT WT
L3723 M 53 19,7 0 WT LS WT WT
L3724 F 34 10,7 4,5 WT WT WT WT
L3725 F 62 15,1 2,6 WT WT WT WT
L3727 F 46 9 1,5 WT LS WT WT
L3728 M 56 13,7 3 WT WT WT WT
L3729 M 52 16,8 4,4 WT LS WT WT
L3730 F 65 11,3 2,8 WT WT WT WT
L3731 F 81 45,9 5,8 WT WT WT WT
L3732 F 69 13,2 8,4 WT WT WT WT
L3734 M 35 24,8 5,1 WT WT WT WT
L3735 F 41 8,3 0 WT WT WT WT
L3736 F 69 24,3 4,2 WT WT WT WT
L3737 M 59 14,2 3,1 WT WT WT WT
L3738 F 60 10,8 2,6 WT WT WT WT
L3739 M 61 9,2 1,8 WT WT WT WT
L3740 F 52 14,6 9,4 WT WT WT WT
L3741 F 71 24,8 2,9 WT WT WT WT
L3742 F 54 12 4,3 WT WT WT WT
L3743 F 38 11,1 3,5 WT WT WT WT
L3744 M 46 7,9 0 WT WT WT WT
L3745 F 56 5,6 5,6 WT WT WT WT
L3746 M 46 49,3 33,9 WT WT WT WT
L3747 F 53 15,4 2,7 WT WT WT WT
WT: wild type signal , LS : Low signal.
63
Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with vestibular schwannomas
4
Figure 2. Example of qPCR results for the BRAF assay.
Table 3b. patient characteristics and qPCR results of larger tumors 
Sample Sex Age (yr) Size (mm) Growth
mm/yr
KRAS EGFR BRAF PIK3CA
L3611 F 39 43 - WT WT WT WT
L3749 F 59 32 - WT WT WT WT
L3613 M 49 36 - WT WT WT WT
L3618 F 49 46 - WT WT WT WT
L3752 M 30 35 - WT WT WT WT
L3753 F 48 3 - WT WT WT WT
L3754 M 51 39 - WT WT WT WT
L3755 F 61 34 - WT WT WT WT
L3756 M 58 43 - WT WT WT WT
L3757 M 65 37 - WT WT WT WT
L3758 F 58 38 - WT WT WT WT
L3759 M 47 30 - WT WT WT WT
L3760 F 21 38 - WT WT WT WT
L3761 F 30 45 - WT LS WT WT
L3762 M 60 30 - WT WT WT WT
L3751 M 60 30 - WT WT WT WT
L3750 F 53 33 - WT WT WT WT
L3748 F 50 35 - WT WT WT WT




In this study we report on the results of an allele specific quantitative real-time PCR assay 
for the most frequent activating mutations of BRAF, EGFR, PIK3CA and KRAS in 48 
sporadic vestibular schwannomas. The allele specific quantitative real-time hydrolysis probe 
PCR assay that was conducted is a reliable and highly sensitive technique for the detection 
of mutational hotspots in the BRAF, EGFR, PIK3CA and KRAS genes. 
Using this technique no mutations could be demonstrated. The fact that no mutations were 
found in this cohort of 48 tumors suggests that hotspot activating mutations of BRAF, EGFR, 
PIK3CA and KRAS do not play a significant role in sporadic vestibular schwannoma 
pathogenesis. This outcome supports the results by Shindler et al. but remains in contrast 
with the findings of Serrano et. al. 17. They detected BRAF mutations in 3 out of 16 
investigated sporadic non head and neck schwannomas. The origin of the schwannomas 
investigated by Schindler et al was not specified but maybe analogous to the situation in 
the uveal melanomas, which in contrast to cutaneous melanomas very rarely contain BRAF 
mutations 46,47, there is a location dependency for BRAF mutations in sporadic schwannomas 
as well. So far the biological mechanisms responsible for this apparent location dependent 
incidence of BRAF mutations remain unclear. 
Next to BRAF, EGFR has been analysed in earlier studies on schwannoma pathogenesis 
as well. An immunohistochemical study on 22 vestibular schwannomas by Sturgis et al. 48 
demonstrated positivity for EGFR in three fourths of their samples. Prayson et al. investigated 
EGFR via immunohistochemistry and fluorescent in situ hybridization but was not able to 
detect any EGFR expression or amplification 49. The later study combined with our results 
indicate that if EGFR is upregulated in schwannomas this probably is not caused by changes 
to the gene itself  but more likely a result of diminished inhibition by its upstream regulator 
NF2 50. 
To date the genetic profile of vestibular schwannomas has not been fully characterized.  As 
mentioned before, the major genetic alteration involved in sporadic vestibular schwannoma 
genesis is inactivation of the NF2 gene. However, there seems to be a subpopulation of 
tumors without a proven NF2 mutation6-8,11. One explanation for this subpopulation might 
be the involvement of genes other then NF2 but so far no clear evidence proving the 
presence of such genes has been provided. Another explanation could be that the mutation 
detection techniques that have been used were simply not sensitive enough. Even the most 
extensive mutation assays did not cover the entire NF2 gene 51. Other factors that may 
have reduced the sensitivity of these tests are contamination of tumor tissue or epigenetic 
processes like aberrant methylation 15,52. 
Recent developments in DNA sequencing technologies like “next-generation sequencing”53 
make analysis of the entire NF2 gene, including epigenenomic assays 54, possible and 
might offer solutions to clarify this matter. If indeed all sporadic vestibular schwannomas 
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arise by inactivation of NF2 and no other genetic alterations play a major role in vestibular 
schwannoma biology the question remains which other mechanisms are responsible for 
these tumors’ phenotypical variability. 
In this context we have recently performed a pilot study which focussed on the intratumoral 
microenvironment of the vestibular schwannoma and its role in tumor growth55. In this study 
we detected CD68 positive macrophages in a majority of tumors; the expression rate of 
these macrophages correlated with the degree of tumor vascularisation and with clinical 
markers of tumor growth. The importance of the intratumoral inflammatory microenvironment 
has been established in several types of cancer 56 and might be an important biological 
mechanism affecting tumor growth of the vestibular schwannoma as well. 
In summary we conclude that the most frequent mutations affecting BRAF, EGFR, PIK3CA 
and KRAS do not play a major role in sporadic vestibular schwannoma biology. So far no 
genes other than NF2 have been proven to be associated with this type of tumor. Whether 
the variable growth pattern of sporadic vestibular schwannomas is based on a specific 
genetic background or other biological mechanisms such as the intratumoral 
microenvironment remains to be established.
Source of Funding and conflict of interest statement: departmental grant, the authors 
declare there is no conflict of interest concerning materials or methods used in this study 
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Tumor-associated macrophages are related to 
volumetric growth of vestibular schwannomas
CHAPTER 5
Abstract
Objective: assess whether the expression of CD163 positive macrophages in sporadic 
vestibular schwannomas is associated with angiogenesis and tumor growth. 
Background: an important clinical problem regarding vestibular schwannoma treatment 
is their variable growth rate. Tumor biological research can help to clarify this growth rate 
and may offer targets for therapy. Inflammation is an important biological process involved 
in the development of many solid tumors. Macrophages are major determinants of 
intratumoral inflammation. Macrophages can be divided into two groups; the M1- and M2-
type macrophages. M2-type macrophages are associated with tumor promoting processes 
like angiogenesis, tumor cell growth and downregulation of the antitumor immune response. 
Both macrophages and angiogenesis can serve as targets for therapy. CD163 is a specific 
marker for M2-type macrophages. 
Methods: CD163 expression in 10 fast growing vestibular schwannomas was compared 
with CD163 expression in 10 slow growing vestibular schwannomas. Tumor growth was 
determined by comparing preoperative tumor volume measurements on MRI. The relation 
between macrophage expression and angiogenesis was evaluated by assessing microvessel 
density (CD31).
Results: CD163 expression and microvessel density were significantly higher in fast 
growing vestibular schwannomas (p<0,001 and p=0,019 respectively). Tumors with higher 
CD163 expression contained significantly more microvessels (p=0.014).
Conclusion: this study demonstrates that M2-type macrophages in vestibular schwannomas 
relate to angiogenesis and volumetric tumor growth. These results imply that the M2-type 
macrophage infiltrate contributes to progressive tumor growth making it a potential target 
for pharmacological therapy.
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Introduction
Vestibular schwannomas are benign tumors recapitulating the differentiation repertoire of 
the myelin-forming Schwann cells of the vestibular branch of the eighth cranial nerve in the 
internal auditory canal or the cerebellopontine angle. These tumors grow slowly and 
progressively, ultimately causing brainstem compression. Therapeutic management of 
vestibular schwannomas can be divided into three main strategies i.e. microsurgery, 
stereotactic radiotherapy or serial radiological observation, also known as the wait & scan 
policy. So far, unlike neurofibrosis type 2-related tumors 1,2, sporadic vestibular schwannomas 
are not pharmacotherapeutically treated One of the main problems in determining the most 
suitable strategy is the large variability in growth rate these tumors can display. More 
understanding of this variable growth rate would be of great benefit when determining the 
most suitable therapeutic approach. This requires more insight into tumor biological factors 
affecting vestibular schwannoma growth. Studying vestibular schwannoma biology not only 
contributes to a better understanding of its growth pattern, it may also help to identify 
potential therapeutic targets. 
Recently we have performed a pilot study on histopathological characteristics of vestibular 
schwannoma growth which indicated a significant correlation between CD68 positive 
macrophages and clinical tumor growth 3. So far little is known about the mechanism and 
biological value of the inflammatory process in vestibular schwannomas. A possible 
explanation may come from research on other types of tumors 4-9. It is supposed that the 
inflammatory microenvironment has many tumor promoting effects 10. One of the major 
determinants of the inflammatory infiltrate are macrophages 11. These so called tumor 
associated macrophages (TAMs) can, based on their immunological functions, roughly be 
divided into two different categories 12. The first category comprises the classically activated 
or M1 type macrophages. M1 macrophages have a defensive purpose; they are inflammatory 
and initiate cytotoxic responses against tumor cells and intracellular pathogens 13,14. 
Monocytes differentiate into M1 type macrophages in response to signals produced by 
bacterial products like lipopolysaccharides or by cytokines such as IFNγ 15. M1 macrophages 
are characterized by the expression of proinflammatory cytokines such as IL-12, IL-1 and 
IL616. Upon activation M1 macrophages start to produce nitric oxide and reactive oxygen 
species, they stimulate cytokine-induced cytotoxicity and promote natural killer and T-cell 
activity. Altogether these processes result in a strong antitumor effect. The alternatively 
activated M2 macrophages on the other hand possess different functions. Monocytes 
differentiate into M2 type macrophages in response to cytokines like IL-4 and IL-13 17. M2 
macrophages express scavenger receptors such as CD163 4,15,18-22 and are associated with 
production of for instance IL-10, IL-1b and vascular endothelial growth factor (VEGF). M2 
macrophages dampen anti-tumor inflammatory responses, participate in remodelling and 
repair of damaged tissues and stimulate angiogenesis 11,12,23. The combination of these 
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functions results in a tumor promoting effect. It should be noted that the classification of 
macrophages into M1 and M2 subtypes is an oversimplification of the actual macrophage 
population in order to increase the comprehensibility of macrophage differentiation. 
The aim of this study was to investigate if the expression of M2 type macrophages in 
sporadic vestibular schwannomas is associated with angiogenesis and tumor growth.
Materials and methods
Multiple studies on different types of tumors indicate that the majority of tumor associated 
macrophages are of the M2 type and highly express CD163 19-22, making it an excellent 
marker to study M2 macrophages. We performed immunofluorescent stains against CD163 
on formalin fixed paraffin embedded vestibular schwannoma tissue. To establish the relation 
between macrophage activity and vestibular schwannoma growth we analysed and 
compared the expression pattern of this marker in tumor samples of 10 radiologically 
observed fast growing and 10 radiologically observed slow growing tumors. In order to 
study the association between M2 type macrophage expression and angiogenesis the 
degree of CD31 positive microvessels was evaluated.  
Patient selection
Patients were retrospectively selected from the vestibular schwannoma database at the 
Leiden University Medical Center. The selection involved a group of consecutive patients 
surgically treated for a histologically proven vestibular schwannoma from October 2006 to 
December 2011. Two separate patient cohorts were composed. The first cohort comprised 
10 cases of radiologically observed evident slow growing tumors. The second cohort 
comprised 10 cases of radiologically observed evident fast growing tumors. Decision for 
surgical treatment was based on clinical symptoms (e.g. tinnitus, vertigo and hearing loss), 
the presence of increase of tumor size on sequential MRI scanning and patients personal 
preference. Patients diagnosed with NF2 were excluded from this study.
All patient samples were handled in a coded fashion and all procedures were performed 
according to the ethical guidelines of the Code for Proper Secondary Use of Human Tissue 
in The Netherlands (Dutch Federation of Medical Scientific Societies). 
Tumor measurement
All tumor measurements were conducted on T1-weighted gadolinium enhanced MRI 
examinations and carried out by one and the same author.  Volume measurements were 
performed with a contour measurement method using Vitrea View software (Vital Imaging 
TM, Minnetonka, Minnesota, U.S.A.) (Figure 1). For validation purposes tumor volume was 
measured twice for each MRI scan. The mean of these two measurements was used for 
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further evaluation of tumor growth. Tumor growth rate was determined by comparing tumor 
volume on two sequential MRI scans and expressed in millilitres per year. 
Enzymatic and fluorescent immunostainings
Immunohistochemical stainings were conducted on 4-µm thick slides obtained from formalin 
fixed and paraffin embedded vestibular schwannoma tissue. All stainings were performed 
on one single tumor block per tumor sample. For CD31 (DAKO) enzymatic 
immunohistochemical reactions were carried out according to standard laboratory methods 
24. In brief, heat-induced citrate buffer antigen retrieval was performed using microwave 
treatment of all slides after dewaxing and rehydration, followed by blocking of endogenous 
peroxidase with 3% H2O2/methanol. Primary antibodies were incubated over night at room 
temperature. Slides were incubated with Poly-HRP-Anti mouse/rabbit/rat I 69 (immunologic, 
DVPO 110HRP). Visualisation was carried out in a 3.3’-diamino-benzidine-tetrahydrochloride 
(DAB) solution after the addition of hydrogen peroxide 30% shortly before application. All 
washing procedures were performed in phosphate buffered saline (PBS). Slides were 
counterstained with haematoxylin. 
For CD163 immunofluorescent (Novocastra, Newcastle Upon Tyne, UK) stains were 
performed. After tris EDTA (pH 9.0) heat induced-antigen retrieval the primary antibody was 
incubated over night, followed by incubation with a secondary fluorescent antibody (Alexa 
goat-anti-mouse IgG1 AL-647 (Invitrogen) . 
Figure 1. Example of volume measurement of left sided vestibular schwannoma performed with the contour 




CD163 stained slides were analysed using a confocal laser scanning microscope (LSM510, 
Carl Zeiss, Jena, Germany). This analysis method has been described with regard to 
macrophage expression analysis before 22. Slides were scanned using a fixed laser-filter. 
Alexafluor 647 (red) was exited at 633 nm and detected with a 650 nm long-pass filter. On 
the digitalized scans the fluorescent signal was represented by an artificial colour (red). 
Per scan the microscope was focussed to pick up the maximum amount of fluorescent 
signal.  All images were 1,024 x 1,024 pixels, stack size 521.2 µm x  521.2 µm and a 25x 
objective was used (Figure 2a ,2b).  
All assessments were carried out blinded with regard to clinical tumor characteristics. Per 
tumor slide 5 randomly chosen scans were obtained. These scans were saved in a  JPEG 
Figure 2. CD163 immunofluorescent stain for macrophages in vestibular schwannoma (A) low expression; (B) high 
expression. Original magnification X250. (C) example of the Chalkley count for microvessel density. The circled grid 
points hit CD31 stained micro vessels. Original magnification X 200
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format. Using ImageJ (National Institutes of Health, Bethesda, MD) images were converted 
to a binary configuration. All images were uniformly thresholded and ‘despeckeled’ in order 
to minimize overexposure effects and to reduce background noise. The remaining number 
of positive, red pixels was calculated and expressed as the area fraction which served as 
the score for macrophage expression. The average count of the five scans per tissue slide 
was used for statistical analysis. 
Microvessel density was determined using the Chalkley point overlap technique. This 
technique allows for rapid analysis with a relatively low interobserver variability and has 
been described in detail before 25,26 . In brief, CD31 stained slides were scanned for vascular 
hot spots. Using an ocular grid with 25 random points these hot spots were scored at a 
200x magnification. The grid was orientated to permit the maximum number of points hitting 
the stained microvessels (Figure 2c). The Chalkley count was the average of the maximum 
number of points hitting a microvessel in the three most prominent vascular hotspots per 
tumor slide.
Statistics
The difference in CD163 expression and microvessel density in the slow vs. fast growing 
tumors was determined with the Mann-Whitney U test. Two tests were performed to evaluate 
the relationship between CD163 expression and microvessel density. For the first test the 
total patient cohort (n=20) was divided into two groups with regard to the degree of CD163 
expression. The Mann-Whitney U test was used to compare the degree of microvessel 
density in tumors displaying lower CD163 expression with the degree of microvessel density 
in tumors displaying higher CD163 expression. The second test was a Spearman correlation 
test comparing CD163 expression and microvessel density. For all statistical tests a level 
of significance of p < 0.05 was taken into account. All calculations were performed using 
SPSS inc. software, version 16.0.
Results
Details on patient characteristics are listed in table 1. No significant differences in distribution 
of age, gender and duration of preoperative radiological follow up were observed in the two 
patient cohorts. As expected, there was a significant difference in tumor growth rate and 
tumor volume between the two groups.
Immunofluorescent staining for CD163 was performed on tissue sections obtained from 10 
fast growing and 10 slow growing sporadic vestibular schwannomas. All tumors displayed 
a certain degree of immunopositivity for CD163. CD163 expression was significantly higher 
(p<0.001) in fast growing tumors compared to slow growing tumors (Figure 3a). The degree 
of microvessel density was also significantly higher in fast growing tumors (p=0.019) 
compared to slow growing tumors (Figure 3b). The degree of microvessel density was 
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significantly higher (p=0.014) in tumors displaying high CD163 expression (Figure 3c), and 
the Spearman correlation test showed a significant positive relation (p=0.024; r=0.50) 
between CD163 expression and microvessel density.
Discussion
Many, if not all solid tumors contain a certain degree of inflammation27. Macrophage activity 
is a major determinant of the intratumoral inflammatory microenvironment 11. As mentioned 
earlier, these tumor infiltrating macrophages, especially the alternatively activated M2 type 
macrophages, have been associated with tumor progression by stimulating angiogenesis, 
Table 1. patient characteristics 





mri follow up 
(months)
Slow growing group
L3721 M 60 0.35 0.06 13
L3742 F 54 0.27 0.21 7
L3773 F 52 0.22 0.07 6
L3774 F 50 0.88 0.19 27
L3775 M 53 0.69 0.17 10
L3779 F 51 1.46 0.18 32
L3780 F 56 0.74 0.25 11
L3781 F 44 0.53 0.19 12
L3787 M 58 0.52 0.18 12
L3797 F 60 2.13 0.23 12
mean (±SD) 53.8 (±4.96) 0.77 (±0.59) 0.17(±0.06) 14.2 (±8.46)
Fast growing group
L3725 F 62 3.26 1.33 11
L3731 F 81 14.41 4.41 19
L3733 F 76 11.66 8.84 10
L3740 F 52 2.27 2.50 7
L3741 F 71 7.25 1.83 21
L3745 F 56 5.62 2.18 6
L3746 M 46 30.73 43.98 4
L3792 F 75 6.92 3.43 21
L3793 F 39 7.32 5.52 10
L3805 F 39 23.05 2.90 9
mean (±SD) 59.7 (±15.65) 11.24 (±9.16) 7.69 (±12.94) 11.8(±6.26)
difference fast vs. slow (p) 0.26a 0.41b <0.0001b <0.0001b 0.31b
a Chi-square test, b Mann-Whitney U test, results at p ≤ 0,05 are shown in italic
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tumor cell growth and down regulation of the antitumor immune response. Although the 
majority of studies on macrophages in human tumors support this tumor promoting model 
it should be noted that a number of studies reported contradicting results in which high 
macrophage counts were associated with better prognosis 28-30. Presumably different types 
of tumors give rise to different types of inflammatory infiltrates resulting in different effects 
on tumor development. 
In this study we have compared the expression of the M2 macrophages in a group of 10 
slow growing tumors with the expression of this marker in a group of 10 fast growing tumors. 
We also compared the degree of microvessel density between these two groups and finally 
we investigated the relationship between macrophage expression and microvessel density. 
It should be taken into account that the outcomes of these comparisons remain observations 
of association. There is always a possibility that these findings are epiphenomena of a 
larger biological growth dynamic and therefore not directly linked to one another. 
Figure 3. (A) CD163 expression in slow versus fast growing tumors (Mann-Whitney U test), (B) microvessel density 
in slow versus fast growing tumors(Mann-Whitney U test) and (C) microvessel density in tumors with low versus high 
CD163 expression (Mann-Whitney U test). 
CHAPTER 5
78
We used volumetric measurements to assess tumor size because this technique is more 
precise than the conventional 2 dimensional tumor measurements 31,32 Tumor growth rate 
was measured by comparing tumor volume on serial preoperative MRI scans and expressed 
in millitres per year. As demonstrated in table 1. the group of fast growing vestibular 
schwannomas contained significantly larger tumors than the group of slow growing vestibular 
schwannomas. For this reason our findings might not only be based on tumor growth rate 
alone, they may be a related to overall tumor size as well. 
In this study we only included evidently slow growing tumors and evidently fast growing 
tumors. In reality a significant proportion of vestibular schwannomas display a more 
intermediate growth rate. However, because of the explorative nature of this study we chose 
to leave out this portion of intermediate growing tumors in order to maximize the chances 
of demonstrating or ruling out significant differences between the patient groups.  
The degree of CD163 positive macrophages was significantly higher in the group of fast 
growing tumors. These results indicate that M2 macrophages are associated with fast 
growing vestibular schwannomas. The fact that the fast growing tumors also displayed a 
higher degree of microvessel density combined with the fact that there was a significant 
relationship between macrophage expression and microvessel density supports the concept 
that M2 macrophages play a substantial role in vestibular schwannoma biology. 
Several therapeutic strategies targeting macrophage activity at different levels are currently 
under investigation. There are studies aiming to inhibit the attraction and induction of M2 
macrophages 23,33,34 while others investigate the possibility of redirecting macrophages with 
a tumor promoting M2 phenotype towards macrophages with a antitumor M1 phenotype35. 
If these strategies prove to be effective, tumor associated macrophages might become 
novel therapeutic targets for the treatment of vestibular schwannomas. However, before 
the inflammatory process can be considered a realistic target in vestibular schwannoma 
therapy more extensive research on tumor related effects of macrophages and their 
interactions with other elements of the immune system is required. 
In conclusion, this study demonstrates that M2-type macrophage expression in vestibular 
schwannomas is associated to angiogenesis and volumetric tumor growth. These results 
imply that the M2-type macrophage infiltrate may contribute to the progression of these 
tumors making it a potential target for future pharmacotherapeutical therapy.
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CHAPTER 6
Abstract
Objective: to assess if BCRP is expressed in vestibular schwannomas, plexiform 
neurofibromas and MPNST
Background: peripheral nerve sheath tumors comprise a broad spectrum of neoplasms. 
Vestibular schwannomas and plexiform neurofibromas are symptomatic albeit benign, but 
a subset of the latter pre-malignant lesions will transform to malignant peripheral nerve 
sheath tumors (MPNST). Surgery and radiotherapy are the primary strategies to treat these 
tumors. Intrinsic resistance to drug therapy characterizes all three tumor subtypes. The 
breast cancer resistance protein BCRP is a transmembrane efflux transporter considered 
to play a key role in various biological barriers such as the blood brain barrier. At the same 
time it is associated with drug resistance in various tumors. Its potential role in drug resistant 
tumors of the peripheral nervous system is largely unknown..
 
Methods: immunohistochemical staining for BCRP was performed on a tissue microarray 
composed out of 22 sporadic vestibular schwannomas, 10 plexiform neurofibromas and 
18 MPNSTs. 
Results: sixteen out of twenty-two vestibular schwannomas (73%), nine out of ten plexiform 
neurofibromas (90%) and six out of eighteen MPNST (33%) expressed BCRP. 
Conclusion: BCRP is present in the vasculature of vestibular schwannomas, plexiform 
neurofibromas and MPSNT. Therefore, it may reduce the drug exposure of underlying tumor 
tissues and potentially cause failure of drug therapy.
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Introduction
Peripheral nerve sheath tumors (PNST) are relatively common neoplasm’s that comprise 
a broad spectrum of different subtypes. Most of these tumors are histologically benign such 
as schwannomas and neurofibromas 1,2. Next to these benign tumors there is a subset of 
malignant lesions like the malignant peripheral nerve sheath tumors (MPNST) 3,4. 
Neurofibromas, MPNST and schwannomas are examples of PNST that occur either 
sporadically or as part of hereditary neurocutaneous diseases like neurofibromatosis type 
I (NF1) and neurofibromatosis type II (NF2) respectively. Both these disorders seem to 
result from the inactivation of a classic tumor suppressor gene. Neurofibromas and MPNST 
show loss of NF1 expression.  The NF1 gene is located on chromosome 17q11.2. and 
encodes the tumor suppressor protein neurofibromin 5. NF1 is caused by germline mutations 
in NF1 but there are also mosaic forms of this disease6.  MPNST or plexiform neurofibromas 
without other symptoms of NF1, i.e. sproradic tumors, are probably caused by somatic 
mosaicism for an NF1 mutation. A similar situation is seen in NF2. NF2 is caused by biallilec 
inactivation of the NF2 gene, located on chromosome 22q11,  which encodes the tumor 
suppressor protein merlin7. Bilateral vestibular schwannomas are pathognomonic for this 
rare disease. However, most vestibular schwannomas occur as sporadic unilateral tumors8.
Schwannomas occur in a wide range of anatomical sites, including the subcutaneous tissues 
of the distal extremities and the head and neck region. Schwannomas in the head and neck 
region have a predilection to derive from the vestibular portion of the eighth cranial nerve, 
better known as vestibular schwannomas (VS). Schwannomas are neoplastic proliferations 
that exclusively comprise Shwann cells while neurofibromas contain multiple cell types 
such as perineurial cells, fibroblasts and to a lesser extent Schwann cells 1,9-11 There are 
two types of neurofibromas: dermal and plexiform. Plexiform neurofibromas are strongly 
related to NF1, affecting 20% to 40% of patients suffering from this condition12,13. These 
tumors often occur in the head, skull base, or neck but also manifest themselves on the 
trunk and limbs. Plexiform neurofibromas have the potential to transform into MPNST. 
However, not all MPNST develop from pre-existing neurofibromas, as approximately half 
of all MPNST arise sporadically without a known precursor14. 
These different types of tumors require different types of therapy. To date surgical excision 
is the only effective treatment for plexiform neurofibromas, but recent literature demonstrated 
that targets for pharmacological treatment are emerging15,16.  Therapeutic management of 
(vestibular) schwannomas consist of surgery or radiotherapy and pharmacological treatment 
options were recently tested as well 17. Although there are promising results in individual 
NF2 patients treated with targeted therapy there are also reports indicating drug resistance 
in these tumors18. A similar situation exists in MPNST. The triad of surgery, radiotherapy 
and multi-agent chemotherapy is applied to these tumors as well. Despite promising reports 
on for instance (neoadjuvant) doxorubicin-ifosfamide treatment regimens, these tumors are 
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often characterized by a highly aggressive behavior and resistance to multidrug therapy, 
resulting in poor long-term survival rates 19-21. In short, despite the different therapies that 
are applied to these PNST one of their common dominators is the fact that they show a 
certain degree of drug resistance. 
Acquired and/or innate drug resistance of tumor cells is a common phenomenon and a 
major hurdle to effective chemotherapeutic intervention. An important mechanism 
contributing to drug resistance concerns the expression of ATP binding cassette (ABC) 
transporter proteins that are capable of extruding drugs from tumors22.  These energy-
dependent transmembrane proteins transport a wide range of substrates, including many 
anticancer drugs, across cell membranes 23-27. So far 49 genes have been identified to 
encode for members of the ABC transporter family 28, but only a subset of these is involved 
in drug resistance. Of these drug transporters ABCB1 (P-gp) and ABCG2 (BCRP) are the 
most extensively studied. They were first discovered in tumor cells29,30, but are also 
expressed at the apical membranes of epithelial cells in biological barrier tissues such as 
in the intestines, kidneys and liver and have an important role in the clearance of xenobiotics 
from the body 23. In addition, they are expressed in specialized endothelial cells that form 
the blood-brain, blood-testis and blood-placenta barriers where they help to limit the 
exposure of the underlying tissues (brain, testis and fetus) to xenobiotics 31-33. Besides efflux 
transporters, these specialized endothelial cells also present other barrier properties, such 
as tight junctions and lack of fenestrations that limit para-cellular entry of drugs. In the brain, 
the surrounding glial cells (astrocytes, pericytes) govern the expression of these barrier 
markers in these endothelial cells. The blood-brain barrier (BBB) may thereby “protect” 
tumor cells that reside within the central nervous system 34.Similar to the situation in the 
brain, tumors originating from the peripheral nerve sheath may be protected by the so called 
blood-nerve-barrier (BNB). Our hypothesis is that the blood-nerve-barrier might hinder drugs 
from reaching their target cells in peripheral nerve sheath tumors, thereby contributing to 
drug resistance (Figure 1).  
The three tumor types we included in this analysis were selected because all of them 
originate from the peripheral nerve sheath and, as mentioned earlier,  each of them are 
characterized by some form of drug resistance. The BNB is located in microvasculature of 
the endoneurium and the inner most layers of the perineurium35 and there are reports that, 
analogous to the situation at the BBB, the BNB contains members of the ABC transporter 
family such as BCRP and P-gb 36,37. Apart from the concept of protection by the BNB, these 
tumors may also be drug resistant because the tumor cells themselves express ABC drug 
transporters. Since its discovery, BCRP expression has been observed in several types of 
tumors 38-47 and elevated expression levels of this transporter have been correlated with 
poor prognosis in a number of studies 48-50. Moreover, the expression of BCRP in tumor 
cells has been associated with a rare subset of so-called cancer stem cells, similar to the 
expression of BCRP in normal stem cells 51,52. Consequently, the expression of BCRP both 
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in tumor blood vessels or in tumor cells can mediate drug resistance. 
The aim of this study was to assess the presence and localization of BCRP in peripheral 
nerve sheath tumors. We investigated the expression pattern of BCRP in twenty-two 
sporadic vestibular schwannomas, ten plexiform neurofibromas and eighteen MPNST using 
an immunohistochemical assay performed on a tissue microarray (TMA) composed of these 
tumors. We used TMA technology because it provides the advantage of simultaneously 
analyzing a large panel of tumors with a high degree of experimental standardization53. Is 
has also been shown that the clinico-pathological findings obtained by this technique are 
highly representative of their donor tissues54L.</author><author>Nocito, A.</
author><author>Moch, H.</author><author>Sauter, G.</author></authors></
contributors><auth-address>Institute of Pathology, University of Basel, 4003 Basel, 
Switzerland.</auth-address><titles><title>Tissue microarray (TMA. The results of our 
analysis show that BCRP is expressed in all three of these tumor types. This observation 
indicates that BCRP might reduce drug accumulation in these peripheral nerve sheath 
tumors thus creating a hurdle to effective drug treatment. 
Results
The results from this immunohistochemical, tissue micro array based study indicate the 
presence of BCRP in the microvascular endothelium of MPNST, plexiform neurofibromas 
and vestibular schwannomas (Figure 2). Six out of the eighteen MPNST samples showed 
vascular BCRP expression. Two of the positive specimens were NF1 related and the other 
four were sporadic tumors. Tumor cells were negative for BCRP. One of the studied MPNSTs 
was a recurrent tumor and matched with another specimen in this study. In both cases, the 
vasculature of these samples was BCRP negative. None of the MPNST patients received 
Figure 1. A mechanistic figure of the proposed function of BCRP and P-gb at the blood-nerve-barrier. 
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chemotherapy prior to resection. The vasculature of nine out of ten plexiform neurofibroma 
samples was BCRP positive as well as the vasculature of sixteen of the twenty-two 
schwannomas. Two separate plexiform neurofibroma samples originated from the same 
NF1 patient and both these tumors had BCRP positive vasculature.  Unfortunately, the 
analyzability of some of the MPNST tumor specimens on the TMA slide was impaired due 
to necrosis. We found that in four out of eighteen MPNST cases one or two specimens 
showed intrinsic tumor necrosis making them unsuitable for microscopic analysis. 
Nevertheless, at least one of the three specimens of these tumors contained representative 
tumor tissue. Therefore it was still possible to perform  adequate microscopic analysis on 
tissue from all the tumors in the analysis. Of these four MPNST one was scored positive 
for BCRP and the other three were scored negative.
Discussion
Present treatment of peripheral nerve sheath tumors is mainly a surgical matter. The 
unraveling of the underlying molecular pathologies and the ongoing development of new 
therapeutic agents may provide potentially effective drugs as an alternative- or concomitant 
therapeutic strategy. Unfortunately, however, the occurrence of innate or acquired drug 
resistance of tumors is a common event. Drug resistance is a frequently encountered 
problem in MPNST, but it is also observed in benign or precursor lesions. Multidrug 
resistance is a complex phenomenon and frequently multifactorial. One important reason 
is impaired drug delivery to the target tissues because of the expression of drug efflux 
Figure 2. Immunohistochemistry images showing clear BCRP and CD31 positivity in the microvascular epithelium 
of MPNST(A and B), plexiform neurofibroma (C and D) and vestibular schwannoma (E and F) respectively. Images 
G and H show a CD31 positive yet BCRP negative sample of a vestibular schwannoma.
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proteins in the (micro)vasculature of tumor tissues or because of expression of these 
proteins by tumor cells themselves. In central nervous system (CNS) tissues, the restricted 
entry is due to drug transporters located at the interface between the blood and the brain 
(the BBB). A similar situation may be present at the interface between blood and peripheral 
nerves, but this has not been well established yet. The most extensively studied efflux 
transporters of the BBB are P-gp (ABCB1) 55 and BCRP (ABCG2) 56. Together, these two 
efflux transporters team up to restrict the CNS penetration of a wide range of substrates 
including many potentially useful drugs 56-59. In this study, we have investigated the 
expression of BCRP in tumors of the peripheral nervous system. Based on our results it is 
not entirely clear if the vascular BCRP expression we observed in a selection of the 
investigated tumors is a specific characteristic of these tumors, or if it is a remaining part 
of the blood-nerve-barrier. Dahin et al 60 identified BCRP expression in retinal nerve fibers 
suggesting that BCRP is part of the blood-nerve-barrier that protects retinal nerve fibers 
from injury by removing intracellular toxins and xenobiotics. A contradictory observation 
was made by Huang et al 61 . They investigated BCRP and P-gp in peripheral nerves using 
a tissue distribution assay on rats but did not find a difference in drug distribution between 
wild type- or BCRP/P-gp knock out rats. However, in the Huang study the Abcg2 KO had 
little effect on the brain distribution of known BCRP substrate drugs and these findings are 
at odds with other ABC KO studies and have not been replicated independently 
since.37,62,63Furthermore, they are in stark contrast with multi drug resistance observed in 
clinical studies in NF1 patients with known P-gp and/or BCRP substrate drugs.15,16,64-
66Similarly, prior studies in MPNST confirmed the presence of drug resistant sarcoma stem 
cells67,68 and the P-gp and BCRP efflux pumps47,50,69,70, while drug trials in MPNST patients 
have not improved outcomes50,71 Our findings provide a rationale to further study the 
hypothesis that endothelial BCRP expression may be part of the reason why drug therapy 
of PNST often fails 47. If this hypothesis is correct it could mean that inhibition of BCRP may 
aid in rendering these tumors more susceptible to drug therapy.  A potential strategy to 
achieve this is to co-administer elacridar, a potent, selective inhibitor of both P-gp and BCRP 
with molecularly targeted drugs to enhance drug levels in diseased neural tissues and 
improve outcomes as has been observed in animal models of other pump-protected 
diseases 34,72-82.
In conclusion, our results demonstrate the expression of BCRP in the vascular endothelium 
in a substantial fraction of MPNST, plexiform neurofibromas and sporadic vestibular 
schwannomas. Similar to CNS tumors, the presence of BCRP, and perhaps other members 
of the ABC efflux transporter family, may reduce the drug exposure of underlying tumor 





The cases included in this study were retrospectively selected from the files of the bone- and 
soft tissue tumor database at the department of Pathology of the Leiden University Medical 
Center, Leiden the Netherlands. Tumor specimens were obtained from patients surgically 
treated for their tumors between January 1999 and December 2012. Formalin-fixed paraffin-
embedded samples of twenty-two sporadic vestibular schwannomas, ten plexiform 
neurofibromas and eighteen MPNST were selected. Of these selected tumors two separate 
plexiform neurofibromas originated from the same patient and one MPNST was a recurrence 
of a primary tumor included in this analysis as well. Surgery was performed at the departments 
of Neurosurgery, Otolaryngology, Orthopedic surgery and General surgery of the Leiden 
University Medical Center. In each case the diagnosis was made according to the WHO 
classification of soft tissue tumors 83. All tumor samples were handled in a coded fashion and 
all procedures were performed according to the ethical guidelines of the Code for Proper 
Secondary Use of Human Tissue in The Netherlands (Dutch Federation of Medical Scientific 
Societies). Additional clinicopathological data are shown in table one. 
Tissue microarray (TMA) preparation
Preparation of the TMAs was performed at the department of pathology of the Leiden 
University Medical Center. TMAs were constructed from 1mm cores of all tumor samples 
using a TMA Master (3DHISTECH Ltd, Budapest, Hungary). Per tumor three randomly 
selected cores were included in the TMA in order to compensate for intra-tumoral 
heterogeneity. Normal colon, tonsil, placenta, prostate and spleen tissue together with 
mamma carcinoma were used to serve as internal controls and points of orientation. In line 
with data provided by the manufacturer we found high BCRP expression in placenta and 
low expression in colon tissue. 
Immunohistochemistry (IHC)
Immunohistochemical reactions were performed according to standard laboratory methods 
84. In brief, heat-induced antigen retrieval was performed after dewaxing and rehydration, 
followed by blocking of endogenous peroxidase with 3% H2O2 in methanol. Incubation with 
the primary antibodies BCRP (Abcam; ab24115) and CD31 (Abcam; ab28364) was 
overnight. Subsequently, CD31 sections were conjugated with Labelled Polymer-HRPAnti-
Rabbit Envision (DakoCytomation; K4005) while conjugation of the BCRP sections was 
performed with Goat-α-Rat-Bio (Santa Cruz; SC-2041) and Streptavidin/HRP 
(DakoCytomation; P0397) respectively. Visualization was carried out with a diaminobenzidine 
solution. All washing procedures were conducted in phosphate-buffered saline. Slides were 
counterstained with haematoxylin. 
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Table 1. patient characteristics 
Specimen Tumor Type Sex Age (yrs.) Tumor Localisation Brcp 
L1399 NF1 MPNST F 16 upper leg, right positive
L4304 NF1 MPNST F 29 second thoracic vertebra, left negative 
L4309 NF1 MPNST F 15 mandible angle, right positive
L4326 NF1 MPNST F 27 flank region, left negative 
L1537 sporadic MPNST* M 22 back, middle  negative 
L1448 sporadic MPNST M 51 inguinal region, left negative 
L1219 sporadic MPNST F 35 gluteus region, right negative 
L1503 sporadic MPNST F 58 upper leg, right negative 
L1509 sporadic MPNST M 17 upper arm, left negative 
L1867 sporadic MPNST M 57 upper leg, left negative 
L2056 sporadic MPNST M 24 inguinal region, left positive
L2170 sporadic MPNST M 22 brachial plexus, left negative 
L4303 sporadic MPNST F 41 brachial plexus, left positive
L4320 sporadic MPNST M 22 back, middle  negative 
L4322 sporadic MPNST F 48 brachial plexus, left negative 
L4325 sporadic MPNST F 35 fifth cervical vertebra, left negative 
L4327 sporadic MPNST M 68 retroauricular region, right positive
L4328 sporadic MPNST V 26 fifth cervical vertebra, left positive
L4305 NF 1plexiform neurofibroma F 33 foot, right negative 
L4321 NF1 plexiform neurofibroma M 23 skin of neck, left positive
L4330 NF1 plexiform neurofibroma V 42 supraclavicular region, right positive
L4331 NF1 plexiform neurofibroma M 30 upper leg, right positive
L4332 NF1 plexiform neurofibroma** M 30 occipital region, middle positive
L4333 NF1 plexiform neurofibroma M 24 cheek, left positive
L4335 NF1 plexiform neurofibroma F 31 neck region, left positive
L4302 sporadic plexiform neurofibroma F 27 median nerve left positive
L4329 sporadic plexiform neurofibroma V 26 axilla, right positive
L4334 sporadic plexiform neurofibroma F 51 femoral nerve, right positive
L1493 sporadic schwannoma F 39 cerebellopontine angle, right positive
L3580 sporadic schwannoma M 58 cerebellopontine angle, right negative 
L3583 sporadic schwannoma M 47 cerebellopontine angle, left positive
L3586 sporadic schwannoma F 48 cerebellopontine angle, right negative 
L3590 sporadic schwannoma M 43 cerebellopontine angle, right positive
L3593 sporadic schwannoma F 53 cerebellopontine angle, left positive
L3604 sporadic schwannoma F 43 cerebellopontine angle, right positive
L4306 sporadic schwannoma M 69 cerebellopontine angle, left positive
L4307 sporadic schwannoma F 57 cerebellopontine angle, right positive
L4308 sporadic schwannoma M 73 cerebellopontine angle, right positive




After staining the TMA was scanned using a Pannoramic MIDI Digital Slide Scanner 
(3DHISTECH Ltd, Budapest, Hungary). Analysis of the digital slides took place with 
Pannoramic Viewer software version 1.15.3. Scoring was performed by two observers who 
were unaware of the clinico-pathological data. Staining of tumor specimens was classified 
as either positive or negative. Differently assessed cases were discussed to reach consistent 
scoring results. 
Specimen Tumor Type Sex Age (yrs.) Tumor Localisation Brcp 
L4310 sporadic schwannoma F 59 cerebellopontine angle, right positive
L4311 sporadic schwannoma F 56 cerebellopontine angle, left positive
L4312 sporadic schwannoma F 56 cerebellopontine angle, left positive
L4313 sporadic schwannoma M 43 cerebellopontine angle, right negative 
L4314 sporadic schwannoma F 59 cerebellopontine angle, left positive
L4315 sporadic schwannoma F 61 cerebellopontine angle, right positive
L4316 sporadic schwannoma F 67 cerebellopontine angle, left positive
L4317 sporadic schwannoma F 50 cerebellopontine angle, left positive
L4318 sporadic schwannoma M 55 cerebellopontine angle, left negative 
L4319 sporadic schwannoma F 72 cerebellopontine angle, right positive
L4323 sporadic schwannoma M 62 cerebellopontine angle, right negative 
L4324 sporadic schwannoma F 54 cerebellopontine angle left negative 
* recurrent tumor from specimen L4325; ** separate tumor from the same patient as L4331
Abbrevations
ABC ATP binding cassette 
ABCB1 ATP-binding cassette sub-family B member 1
ABCG2 ATP-binding cassette sub-family G member 2
BBB Blood-brain-barrier
BCRP Breast Cancer Resistance Protein
BNB Blood-nerve-barrier
MPNST Malignant peripheral nerve sheath tumors 
NF 1 Neurofibromatosis type I 
NF 2 Neurofibromatosis type II
P-gb permeability glycoprotein
PNST Peripheral nerve sheath tumors 
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M-CSF and IL-34 expression as indicators for growth
in Sporadic Vestibular Schwannoma  
CHAPTER 7
Abstract
Objective: assess whether macrophage colony stimulating factor and IL-34 are associated 
with clinical vestibular schwannoma progression. 
Background: investigating the biology behind vestibular schwannoma progression helps 
understanding tumor growth. Inflammation is important in the microenvironment of 
neoplasms. Macrophages are major players in the intratumoral infiltrate. These tumor 
associated macrophages are known to stimulate angiogenesis and cell growth. M-CSF and 
IL-34 are cytokines that can regulate tumor infiltrating macrophages. They are expressed 
by tumors and form potential targets for therapy. The goal of this study was to investigate 
these cytokines in vestibular schwannomas and to see if their expression is related to 
angiogenesis, macrophage numbers, cystic degeneration and volumetric tumor progression.
 
Methods: immunohistochemical expression of M-CSF and IL-34 was analysed in ten fast-
growing vestibular schwannomas and in ten slow-growing vestibular schwannomas. 
Expression M-CSF and IL-34 were compared between fast versus slow growing, and cystic 
versus non-cystic tumors. Data on macrophage numbers and microvessel density, known 
from earlier research, was also included.
Results: all tumors expressed M-CSF and its expression was higher in fast growing tumors 
(p=0.003) and in cystic tumors (p=0.035). CD163 expression was higher in tumors with 
strong M-CSF expression (p=0.003). All tumors expressed IL-34 as well, but no significant 
differences were found in relation to clinicopathological characteristics. 
Conclusion: this study demonstrated the expression of M-CSF and IL-34 in vestibular 
schwannomas. The results suggest that M-CSF is related to macrophage activity and tumor 
progression, making it a potential target for therapy. If a similar assumption can be made 
for IL-34 remains unclear. 
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Introduction
Vestibular schwannomas (VS) are benign neoplastic proliferations recapitulating the 
differentiation repertoire of the myelin-forming Schwann cells of the vestibular branch of 
the vestibulocochlear nerve in the internal auditory canal or the cerebellopontine angle. 
These tumors often display a slow and self-limiting growth pattern but there are also variants 
that progress more rapidly and persistently. In these patients ongoing tumor progression 
can eventually cause brainstem compression or paralysis of adjacent cranial nerves. In 
most cases (>90%) VS occur as unilateral sporadic tumors1, whereas bilateral tumors are 
pathognomonic for the hereditary disorder neurofibromatosis type 2 (NF2)2. Loss of function 
of the tumor suppressor protein merlin, encoded by the NF2 gene, is an essential step in 
schwannoma pathogenesis3,4.  Heterozygous germline inactivating mutations affecting the 
NF2 gene cause neurofibromatosis type 2 while biallelic somatic mutations of NF2 are 
found in sporadic VS4. Recent years showed an increase in the number of newly diagnosed 
VS to approximately 20 per million people per year 5-7. This phenomenon most probably is 
the result of more frequent use of magnetic resonance imaging scanning (MRI), which in 
turn leads to the identification of more subclinical cases of VS. 
Management of these VS comprises several options. The initial policy for smaller tumors 
is to wait and see by performing sequential MRI scans. In case of large tumors or when 
tumors rapidly progress active treatment is needed. Current therapeutic management of 
VS consists of microsurgery or radiotherapy. In selected cases of NF2 related tumors 
pharmacotherapeutic options are also applied 8-10.  This kind of therapy is not used for 
sporadic VS. One of the clinical dilemmas in selecting the most suitable treatment policy 
for VS is the unpredictable behavior these tumors can display. Some tumors remain stable 
for decades while others double in size within less than a year. So far, cystic degeneration 
is the only known prognostic marker for progressive tumor volume growth11. Better prediction 
of tumor volume progression will improve the accuracy of determining the correct moment 
and modality of therapeutic intervention. More understanding of tumor behavior requires 
more insight into tumor biological factors influencing tumor development. Investigating VS 
biology not only benefits the understand ding of its growth pattern, it will also contribute to 
the identification of potential therapeutic targets. 
In two earlier papers on the inflammatory microenvironment in VS we demonstrated a 
relationship between tumor associated macrophages (TAM) , angiogenesis and tumor 
growth12,13. These results were in line with the emerging notion that intratumoral inflammation 
is a major driving force behind the volumetric progression of tumors 14-16. The fact that TAM 
may form a target for therapy emphasizes their potential clinical importance 17. TAM consist 
of a heterogeneous population of, mainly alternatively activated, M2 type macrophages 
that seem to have tumor promoting characteristics 16,18. Inhibiting the formation of M2 
macrophages may therefore have a negative effect on tumor progression. An important 
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regulator within the inflammatory microenvironment capable of polarizing macrophages 
towards an M2 like phenotype is a cytokine known as the macrophage colony stimulating 
factor, or M-CSF19. The exact role of M-CSF in macrophage associated tumor development 
remains to be elucidated but its function as a promoter of tumor progression has been 
indicated in several tumor models 20-22. Another regulating protein that seems to be capable 
of skewing the microenvironment into a tumor promoting direction is interleukin-34 (IL-34). 
This cytokine was first described in 2008 by Lin et. al. 23 and displays common features 
with M-CSF in such a way that they appear to have synergistic functions24,25. Consistent 
with these findings relatively recent studies have indicated that IL-34 seems to be associated 
with tumor progression in osteosarcoma and lung cancer26,27. 
The aim of this study was to analyze the expression of M-CSF and IL-34 in our earlier 
described cohort of twenty sporadic vestibular schwannoma patients and to determine 
whether their expression can be related to clinicopathologic characteristics and tumor growth. 
Materials and methods
We performed immunohistochemical stains against M-CSF and IL-34 on formalin-fixed 
paraffin-embedded vestibular schwannoma tissue. To investigate whether there is a 
relationship between the presence of these proteins and VS progression we analyzed their 
expression pattern in the same selection of tumors that we previously analyzed and 
described for the expression of tumor associated macrophages12.  This selection of tumor 
samples consisted of ten radiologically observed fast growing tumors and ten radiologically 
observed slower growing tumors. The expression patterns of M-CSF and IL-34 within these 
groups were compared with each other. The already published data on angiogenesis and 
macrophage expression was also included into this analysis, as well as radiological data 
regarding cystic degeneration.
Patient selection
A retrospective selection was made from vestibular schwannoma database of the Leiden 
University Medical Center. This group of patients had been consecutively treated for a 
proven sporadic vestibular schwannoma from January 2006 to December 2011. Two 
different cohorts were compiled out of a total of forty-six consecutively treated patients. All 
patients had at least two preoperative MRI scans on the basis of which volumetric tumor 
growth was measured. The first cohort included the ten patients with the slowest growing 
tumors, while the second cohort included the ten fastest growing tumors. The decision for 
surgical treatment had been based upon symptoms (e.g. vertigo, hearing loss and tinnitus), 
tumor size, tumor growth and patients’ personal preference. No NF2 related tumors were 
included in the analysis. 
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To ensure patients privacy all samples were managed in a coded fashion and all procedures 
were conducted according to the Code for Proper Secondary Use of Human Tissue in the 
Netherlands (Dutch Federation of Medical Scientific Societies). 
Tumor measurement 
The measurement of all tumors was performed on T1-weithed gadolinium enhanced MRI 
scans and conducted by one and the same author. Tumor volume was determined with a 
contour measurement method using Vitrea View software (Vital Imaging, Minnetonka, MN, 
USA). To increase the accuracy of the measurements, each volume was determined two 
times per MRI scan. The mean of these two measurements was used for further evaluation 
of tumor growth. By calculating the difference in tumor volume on sequential MRI 
investigations, tumor growth rate could be determined. Volumetric growth was expressed 
as the increase in milliliters per year. Next to measuring tumor growth rate, the presence 
of cystic degeneration was evaluated. Figure one shows volume measurements of a fast 
growing and a slow growing tumor. 
Immunohistochemistry
Immunohistochemistry was performed on 4 micrometer thick slides acquired form formalin-
fixed paraffin-embedded vestibular schwannoma tissue samples. All staining procedures 
were conducted on one and the same tumor block per tumor sample. The exact materials 
and methods that were applied for the CD31 and CD163 stains are described in the earlier 
mentioned paper on tumor associated macrophages 12. Immunohistochemical stains for 
M-CSF (pré-incubation and incubation in 5% non-fat milk in PBS/1%BSA , 1:100 diluted, 
Anti-M-CSF antibody, ab52864, Abcam, Cambridge, MA, USA)  and IL-34 (pré-incubation 
and incubation in 5% non-fat milk in PBS/1%BSA , 1:3000, Anti-Interleukin 34 antibody, 
Figure 1. A and B show a fast growing tumor with an average growth of 9 ml per year. C and D show a slower growing 
tumor with an average growth of 0.2 ml per year.
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ab224734, Abcam, Cambridge, MA, USA) were performed according to standard laboratory 
methods28. Tonsil served as positive control for M-CSF and hepatocellular carcinoma and 
prostate carcinoma we used as positive control tissues for IL-34. 
Microscopic analysis
Immunostainings were evaluated by two separate observers (M. de Vries and P. 
Hogendoorn) without knowledge of clinical patient data. M-CSF as well as IL-34 showed a 
varying staining pattern with areas of strong expression and areas of weak expression 
within the same tumor. Additionally several tumor specimens showed hemosiderin deposition 
mimicking positive staining. This made computerized quantification less reliable. For this 
reason a semi quantitative immunohistochemistry score of the overall staining intensity was 
made for each tumor sample. Staining intensity was initially categorized as no staining, 
weak staining, moderate staining and strong staining. Exact details regarding M2 
macrophage (CD163) and angiogenesis (CD31) staining and scoring techniques are 
described in our earlier raport12. 
Statistical analysis
The difference in M-CSF and IL-34 expression in fast- versus slow growing tumors and 
cystic versus non-cystic tumors was determined with the Fisher’s exact test. The Mann-
Whitney U test was used to determine the relation between the expression of M-CSF and 
IL-34 and the degree of microvessel density and CD163 expression. This test was also 
used to see if there was a relation between cystic degeneration and CD-163 expression. 
For all statistical tests a level of significance of p<0.05 was taken into account. Calculations 
were made using SPSS version 16.0, IBM, Inc.
Results
Details regarding patient characteristics are listed in Table 1. There were no significant 
differences in distribution of age, sex and duration of preoperative follow-up between the 
two patient groups. As expected, the distribution of tumor growth rate and tumor volume 
as well as cystic degeneration was significantly different in the two groups. Analysis of the 
immunohistochemical stainings showed the following results. All samples were M-CSF 
positive, demonstrating cytoplasmic as well as nuclear expression in an irregular staining 
pattern (Figure 2.). Nine samples showed weak staining, four samples showed moderate 
staining and seven samples showed strong staining. Based on these results we simplified 
the categories of staining to weak and strong staining, the latter being the combination of 
moderate and strong staining. M-CSF staining was significantly higher in the group of fast 
growing tumors (p=0.003). M-CSF expression is also significantly higher (p=0.035) in cystic 
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tumors (table 2). CD163 expression was significantly higher in tumors with strong M-CSF 
expression (p=0.003). There was no significant relation between micovessel density and 
M-CSF expression. 
Analysis of IL-34 showed that all tumors displayed nuclear as well as cytoplasmic 
immunopositivity for this protein (Figure 1). Similar to M-CSF the intratumoral staining 
pattern of IL-34 was irregular. Eight tumors showed moderate staining and the remaining 
twelve tumors showed strong staining. Statistical analysis of our scoring results showed 
no significant differences in IL-34 expression when it comes to tumor growth, cystic 
degeneration, CD-163 expression or microvessel density.  
Finally, cystic tumors showed a significantly higher degree of CD-163 expression compared 
to non-cystic tumors (p =0.005).  
Figure 2. A. weak expression of M-CSF, B. strong expression of M-CSF, C. a tissue area with weak IL-34 expression, 




Inflammation is an important feature of almost every type of neoplasm. The inflammatory 
process that takes places within tumors is often characterized by the abundance of tumor 
associated macrophages16. The influx of these cells and their immunomodulating capacities 
allow the progression of tumor cells by stimulating processes such as of angiogenesis and 
cell survival15. M-CSF and IL-34 are cytokines that regulate macrophage recruitment, 
proliferation and differentiation 24. More specifically, M-CSF and recently also IL-34 are 
identified as important factors that polarize macrophages towards a protumoral M2 
phenotype22,27. High M-CSF expression and subsequent increased macrophage levels have 
Table 1. patient characteristics 













L3721 M 60 0.35 0.06 13 no
L3742 F 54 0.27 0.21 7 yes
L3773 F 52 0.22 0.07 6 no
L3774 F 50 0.88 0.19 27 no
L3775 M 53 0.69 0.17 10 no
L3779 F 51 1.46 0.18 32 yes
L3780 F 56 0.74 0.25 11 no
L3781 F 44 0.53 0.19 12 no
L3787 M 58 0.52 0.18 12 no
L3797 F 60 2.13 0.23 12 no
mean (±SD) 53.8 (±4.96) 0.77 (±0.59) 0.17(±0.06) 14.2 (±8.46)
Fast growing group
L3725 F 62 3.26 1.33 11 no
L3731 F 81 14.41 4.41 19 yes
L3733 F 76 11.66 8.84 10 no
L3740 F 52 2.27 2.50 7 no
L3741 F 71 7.25 1.83 21 yes
L3745 F 56 5.62 2.18 6 yes
L3746 M 46 30.73 43.98 4 yes
L3792 F 75 6.92 3.43 21 yes
L3793 F 39 7.32 5.52 10 yes
L3805 F 39 23.05 2.90 9 yes
mean (±SD) 59.7 (±15.65) 11.24 (±9.16) 7.69 (±12.94) 11.8(±6.26)
difference fast vs. slow (p) 0.26a 0.41b <0.0001b <0.0001b 0.31b 0,007a
a Chi-square test, b Mann-Whitney U test, results at p ≤ 0.05 are shown in italics
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been associated with disease progression and unfavorable outcome in several types of 
tumors20,21,29 and similar findings are reported for IL-3426,27. 
Our earlier studies showed that VS can contain large quantities of TAM, and their presence 
seems to be related to tumor expansion. In this study we attempted to find out if M-CSF 
and IL-34 are part of this process as well by comparing their expression pattern in 
progressive versus more indolent VS. A necessary condition to examine tumor tissue is 
that patients are surgically treated. One of the main indications for surgery is tumor growth. 
Even the group of slow growing tumors showed a certain form of volumetric growth and 
therefore did not fully represent the truly indolent tumors. This unavoidable selection bias 
makes the identification of biological differences between indolent versus progressive 
variants of VS more challenging. 
In this report we demonstrate the presence of M-CSF and IL-34 in VS. The expression of 
M-CSF is higher in fast growing VS compared to slower growing VS and, in accordance 
with its supposed function, the presence of M-CSF seems to be related to the expression 
of TAM within VS. Furthermore, the expression of M-CSF as well as the number of CD-163 
positive macrophages appears to be higher in cystic tumors. We therefore postulate that 
intratumoral inflammation might also contribute to the pathogenesis of cystic degeneration. 
We could not demonstrate a relation between IL-34 expression and clinicopathologic 
characteristics of VS in our study group. Nevertheless it should be noted that this protein 
was at least moderately expressed by all tumors, more than half of which even showed 
high immunopositivity. These relatively small intertumoral differences in expression of IL-34 
together with the above mentioned selection bias may be a reason why we were unable to 
find a significant difference in the expression pattern of this protein. 
It is important to note that the results of our comparisons are observations of association. 
Table 2. Fisher’s exact test for M-CSF and IL-34 expression  
M-CSF staining IL-34 staining
Weak Strong Moderate Strong
Growth rate
Slow 8 2 4 6
Fast 1 9 4 6
Total 9 11 8 12
P-value 0.003 0.675
Cystic degenration
No 7 3 5 5
Yes 2 8 3 7
Total 9 11 8 12
P-value 0.035 0.325
results at p ≤ 0.05 are shown in italics
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There is always the possibility that these findings are epiphenomena of a larger biological 
growth process and therefore not directly related to each other. The fact remains that the 
results of this study seem to be in line with our earlier presented data on macrophage 
expression in VS.  These current observations provide additional support for our hypothesis 
that the inflammatory microenvironment plays an essential role in the progression of these 
tumors. By modulating the characteristics of this microenvironment through the inhibition 
of M-CSF, and maybe IL-34, the progression of VS may in turn be decreased. For M-CSF 
several clinical trials with inhibitors such as PLX3397 (Pexidartinib) and RG7155 
(Emactuzumab) showed promising results in a variety of neoplasms 30,31. IL-34 might be a 
potential target as well but clinical evidence remains to be provided32. Before applying anti-
M-CSF or anti-IL-34 therapy in VS patients in vivo schwannoma models would be very 
helpful to further elucidate the biological mechanisms that are involved in the associations 
observed in this study. Unfortunately the current lack of sporadic vestibular schwannoma 
cell lines hampers such functional studies. 
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Vestibular schwannomas are benign tumors recapitulating the differentiation repertoire of 
the Schwann cells that are part of the nerve sheath that insulates the vestibular portion of 
the eighth cranial nerve. These tumors classically arise within the internal auditory canal 
and usually progress into the cerebellopontine angle. One of the clinical hallmarks of these 
tumors is their capricious growth pattern. A significant portion of tumors are limited in size 
and remain indolent after they have been diagnosed. In contrast to this relatively harmless 
phenotype there are also tumors with a faster and more extensive growth pattern that are 
capable of causing brainstem compression or paralysis of adjacent cranial nerves1. This 
unpredictable behavior is one of the main clinical problems in the optimal management of 
vestibular schwannomas. Current treatment comprises observation by sequential MRI 
scanning for smaller and indolent tumors. For larger tumors, tumors that display rapid growth 
or in case of major symptoms, such as invalidating vertigo, active treatment in the form of 
radiotherapy or microsurgery is indicated. Pharmacotherapeutic alternatives are emerging 
but they are not part of standard treatment yet. 
The different studies on which this thesis is based have the general aim to increase current 
insights into the intratumoral biological dynamics associated with vestibular schwannoma 
progression. Enlarging our tumor biological knowledge helps to interpret tumor growth 
patterns which in turn is paramount to the search for prognostic markers and targets for 
therapy. 
Chapter one serves as a general introduction to vestibular schwannomas with regard to 
their aetiology, symptoms and the diagnostic tools that are used for their detection. This 
chapter also provides an overview of current therapeutic management and it discusses the 
clinical dilemmas involved in the treatment of these tumors that have resulted in the research 
questions which form the basis of this thesis. 
Chapter two is a review of the literature on the tumor biology of vestibular schwannomas. 
It describes current knowledge on the genetic profile of these tumors and provides an 
overview of the cell signalling pathways associated with vestibular schwannoma progression. 
The role of angiogenesis as an important factor in tumor growth is discussed, as well as 
its potential function as a target for therapy. Other targets for therapy are also summarized 
and potential subjects of future research are briefly addressed. 
Chapter three investigates a selection of intratumoral processes that take place within 
vestibular schwannomas in order to identify biological factors that contribute to tumor 
progression. Tumor specimens of sixty-seven vestibular schwannoma patients were 
immunohistochemically analysed for cell proliferation (Ki-67, Histone-H3), neovascularisation 
(CD31) , macrophage expression (CD68)  and the presence of intratumoral bleeding 
(hemosiderin). In this study we find no association between cell proliferation and clinical 
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characteristics of tumor growth. On the other hand, factors like neovascularisation and 
macrophage expression do seem to be related to tumor size and the tumor growth index. 
Additionally we find that intratumoral bleeding occurs to a higher degree in tumors that 
show cystic degeneration, which in turn is a known process contributing to tumor expansion1. 
We therefore hypothesize that growth of vestibular schwannomas is not based on cell 
proliferation alone, factors like degenerative changes, angiogenesis and inflammation 
influence progressive tumor growth as well. 
Chapter four describes a gene expression assay for the thirteen most frequent mutations 
affecting BRAF, EGFR, PIK3CA and KRAS. The products of these genes are members of 
the MAPK/ERK cell signalling pathway. Increased activity of this pathway is associated with 
progression of different types of tumors including vestibular schwannomas2,3. This knowledge 
combined with the finding of BRAF mutations in a number of sporadic non head and neck 
schwannomas 4 lead us to investigate the hypothesis that vestibular schwannoma 
progression is influenced by the occurrence of accessory oncogenic mutations related to 
the MAPK/ERK pathway.  We performed a gene expression assay in a selection of forty-
eight vestibular schwannomas, all of which turned out to be negative for any of the mutations 
that were tested. This finding therefore doesn’t support the hypothesis that vestibular 
schwannoma progression is accelerated by additional oncogenic mutations that arise during 
the development of these tumors. 
Chapter five is a study that further investigates the role of inflammation within vestibular 
schwannomas. As described in chapter three, some vestibular schwannomas contain large 
amounts of macrophages. During the past decades it has become clear that in various 
types of neoplasms the inflammatory microenvironment has many tumor promoting effects5. 
Macrophages are one of the major determinants of this microenvironment6. These so called 
tumor associated macrophages can roughly be divided into two groups consisting of the 
classically activated M1 type macrophages versus the alternatively activated M2 type 
macrophages. Of these two categories the M2 type macrophages are the ones with the 
tumor promoting characteristics such as stimulating angiogenesis and dampening of the 
antitumor immune response7.  Using immunofluorescent stains against CD163, a specific 
marker for M2 type macrophages, we determined the expression of M2 macrophages in 
tumor samples of twenty retrospectively analysed vestibular schwannoma patients. We 
also determined the degree of angiogenesis within these tumors. The results of this study 
indicate that some vestibular schwannomas contain large amounts of M2 type macrophages 
and additionally there seems to be a positive relation between the expression of these 
macrophages and angiogenesis as well as tumor growth rate. These results imply that 
tumor infiltrating M2 type macrophages may stimulate the progression of vestibular 
schwannomas, which in turn makes them a potential target for therapy. 
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Chapter six describes a study that investigates BCRP expression as a potential cause of 
drug resistance in a selection of peripheral nerve sheath tumors. BCRP is a transmembrane 
efflux transporter protein that seems to play an important role in different biological barriers 
such as the blood-brain-barrier8,9. Its presence has also been associated with drug 
resistance in cancer10. An immunohistochemical staining for BCRP was performed on a 
tissue microarray composed out of twenty-two sporadic vestibular schwannomas, ten 
plexiform neurofibromas and eighteen malignant peripheral nerve sheath tumors. The 
findings of this study demonstrate the expression of BCRP in the vasculature of a significant 
portion of all three tumor types included in the assay.  It is possible that this endothelial 
expression of BCRP is a specific characteristic of these tumors but it may very well also be 
is a remnant part of the blood-nerve-barrier of the nerves these tumors originate from. 
Nonetheless these results suggest that BCRP expression may reduce drug exposure to 
the underlying tissue in these tumors. This may be part of the reason why drug therapy of 
peripheral nerve sheath tumors, including vestibular schwannomas, often has variable and 
disappointing effects. If this hypothesis is correct, inhibiting BCRP expression in these 
tumors could subsequently lead to enhanced susceptibility to drug therapy. 
Chapter seven forms the sequel to the analysis of the tumor associated macrophages 
described in chapter five. This study comprises the same patient cohort and focusses on 
two cytokines, M-CSF and IL-34. Both these proteins are known to have regulatory functions 
with regard to macrophage activation. M-CSF stands for macrophage colony stimulating 
factor, a cytokine that is capable of polarizing macrophages towards a M2 like phenotype. 
The exact tumor biological characteristics of this protein have not been fully understood 
yet, but there are several tumor models in which it seems play a role in macrophage 
associated tumor progression11,12. IL-34 is a cytokine that displays common features with 
M-CSF13,14. Relatively recent studies have indicated that IL-34 appears to be related to 
tumor progression in a manner that resembles M-CSF15.  Our study demonstrates the 
expression of these two cytokines in vestibular schwannomas. In accordance with its 
proposed function we find that M-CSF expression is related to clinical tumor progression 
and the expression of M2 type macrophages. We were unable to demonstrate similar 
significant findlings for IL-34, but the fact that this protein has a relatively high expression 
in all the VS we investigated does suggest it plays a role in VS biology. These observations 
are in line with the hypothesis that the inflammatory microenvironment is an important factor 
in the progression of vestibular schwannomas. This makes M-CSF, and maybe IL-34 as 




The overall aim of this thesis is to shed more light on the biological background of the clinical 
progression of sporadic vestibular schwannomas. In case of vestibular schwannomas tumor 
progression is measured by the increase in tumor size. The obvious factors that determine 
vestibular schwannoma size seem to be cell growth and cystic formation. 
The results of our studies indicate that, in different ways, intratumoral inflammation seems 
to be important in the clinical progression of these tumors. By stimulating angiogenesis and 
through inhibition of antitumor immune responses tumor associated macrophages may 
allow some tumors to progress faster and reach a larger volume. Next to permitting ongoing 
tumor cell proliferation it might be possible that in some tumors the actual bulk of the 
inflammatory infiltrate also contributes to the expansion of vestibular schwannomas. 
M-CSF and IL-34 may play a regulatory role when it comes to macrophage activity within 
vestibular schwannomas, thereby potentially making them targets for therapy. These 
outcomes must be interpreted with caution. It is important to note that the results of the 
comparisons we made are observations of association. There is always the possibility that 
these findings are epiphenomena of a larger biological growth process and therefore not 
directly related to one another. Before treating VS patients with drugs capable of modulating 
the intratumoral microenvironment our findings need to be replicated, and in vitro or animal 
schwannoma models should be performed. Interesting examples of such drugs are PLX3397 
(Pexidartinib) and RG7155 (Emactuzumab)16,17. Both are relatively new inhibitors capable 
of blocking macrophage activity and, considering our hypothesis, potentially form effective 
agents in vestibular schwannoma therapy. 
In the search for new drugs capable of targeting tumor biological factors involved in the 
progression of vestibular schwannomas it is important to realize that our findings also 
indicate that these tumors may be protected by barrier proteins such as BCRP. Future 
research should reckon with this additional obstacle in order to optimize the efficacy of 
novel treatment strategies. 
Next to looking for new pharmacologic ways to treat vestibular schwannomas there are 
other clinical questions and dilemmas that need to be explored. An important issue that 
needs further research is the potential superiority of proton radiotherapy over the 
conventional radiotherapy. Current literature on this topic is not decisive and clinical trials 
are needed to answer this question. The ongoing development of new therapeutic modalities 
also has its impact on shared decision making when it comes to choosing the correct form 
of therapy. For this reason continuous research in terms of quality of live is of great 
importance in order to tailor future treatment to the individual needs of the patient. 
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Vestibularis schwannomen zijn goedaardige tumoren die ontstaan vanuit een ongeremde 
deling van Schwanncellen die deel uitmaken van de zenuwschede die de vestibulaire tak 
van de achtste hersenzenuw omvat. Doorgaans ontstaan deze tumoren in de inwendige 
gehoorgang waarna ze zich uit kunnen breiden in de brughoek regio. Om deze reden staat 
dit type tumor ook wel bekend als de brughoek tumor. Eén van de klinische kenmerken van 
vestibularis schwannomen is het grillige groeipatroon dat ze kunnen vertonen. Een groot 
deel van deze tumoren blijft nadat ze gediagnostiseerd zijn beperkt in omvang en vertonen 
weinig tot geen groei. Echter zijn er ook exemplaren die een agressiever gedrag vertonen 
waarbij aanhoudende groei kan leiden tot hersenstam compressie of uitval van nabijgelegen 
hersenzenuwen 1 Tot op heden is het grotendeels onduidelijke welke biologische processen 
aan deze verschillende groeiwijzen ten grondslag liggen. Deze onvoorspelbaarheid in tumor 
groei is één van de voornaamste klinische problemen in de behandeling van vestibularis 
schwannomen. Het huidige palet aan behandelopties bestaat uit observatie met behulp 
van periodieke MRI scans in het geval van kleinere en langzaam groeiende tumoren terwijl 
grotere of sneller groeiende tumoren worden behandeld met radiotherapie of microchirurgie. 
Medicamenteuze therapieën zijn in opkomst maar worden nog niet als standaard 
behandeling voor sporadische vestibularis schwannomen toegepast. 
De verschillende onderzoeken die de basis van dit proefschrift vormen hebben als 
gemeenschappelijke doel om meer inzicht te verkrijgen in de tumorbiologische processen 
die zich afspelen in vestibulaire schwannomen. Meer kennis over deze processen is nodig 
voor het interpreteren van de verschillende groeipatronen en een essentiële voorwaarde 
voor het vinden van prognostische markers en aangrijpingspunten voor therapie. 
Hoofdstuk één is een algemene introductie over de etiologie, symptomen en diagnostiek 
van het vestibularis schwannoom. Daarnaast bevat dit hoofdstuk een overzicht van de 
huidige behandelopties en het beschrijft een aantal klinische dilemma’s die in de praktijk 
een rol spelen en de basis vormen voor de onderzoeksvragen van onze studies.
 
Hoofdstuk twee is een review van de literatuur over de tumor biologie van vestibularis 
schwannomen. Het geeft een beschrijving van de huidige kennis van het genetische profiel 
van deze tumoren en het bevat een overzicht van de verschillende cell signalling pathways 
die een rol lijken te spelen in tumor groei van vestibularis schwannomen. De functie van 
angiogenese als groeifactor en daarmee aangrijpingspunt voor therapie wordt besproken 
evenals een aantal andere potentiele doelwitten voor medicamenteuze behandeling. 
In hoofdstuk drie wordt een aantal intratumorale processen onderzocht die plaatsvinden 




Tumor weefsel van in totaal zevenenzestig patiënten is met behulp van immunohistochemie 
onderzocht op cel proliferatie (Ki-67, Histone H3), neovascularisatie (CD31), macrofagen 
expressie (CD68) en intratumorale hematoomvorming (hemosiderine). Deze studie toont 
geen associatie tussen proliferatie en klinische kenmerken van tumor groei. Echter valt 
neovascularisatie en expressie van macrofagen wel te relateren aan tumor omvang en de 
tumor growth index. Tevens lijkt intratumorale hematoomvorming in hogere mate voor te 
komen in tumoren met cysteuze degeneratie, een proces waarvan bekend is dat het 
bijdraagt aan tumor expansie1. Op basis van deze resultaten baseren we de hypothese dat 
de groei van vestibularis schwannomen niet alleen het gevolg is van toegenomen cel 
proliferatie. Factoren zoals cysteuze degeneratie, angiogenese en ontsteking lijkten ook 
van invloed op tumor groei.
Hoofdstuk vier beschrijft een gen expressie analyse naar de dertien meest voorkomende 
mutaties in de genen BRAF, EGFR, PIK3CA en KRAS. De eiwitten waar deze genen voor 
coderen maken deel uit van MAPK/ERK cel signaleringscascade. Toegenomen activiteit 
van deze cascade wordt gezien in verschillende tumoren waaronder ook vestibularis 
schwannomen 2,3.  Deze kennis en de vondst van BRAF mutaties in sporadische, niet 
hoofd-hals, schwannomen 4 gaf aanleiding de hypothese dat groei van vestibularis 
schwannomen beïnvloed kan worden door secundaire oncogenetische mutaties met 
betrekking op de MAPK/ERK cascade te onderzoeken. Een selectie van achtenveertig 
sporadische vestibularis schwannomen is gescreend op de aanwezigheid van deze mutaties 
waarbij geen enkele mutatie is aangetroffen. Deze uitkomst geeft daarmee geen 
ondersteuning aan de hypothese dat de groei van vestibularis schwannomen versneld kan 
worden door het optreden van secundaire oncogenetische mutaties.
Hoofdstuk vijf is een studie die verder ingaat op de rol van ontsteking in vestibularis 
schwannomen. Zoals ook beschreven in hoofdstuk drie lijkt het zo te zijn dat sommige 
tumoren grote hoeveelheden macrofagen bevatten. Gedurende de afgelopen jaren is in 
toenemende mate duidelijk geworden dat in verschillende typen tumoren het inflammatoire 
micromilieu een bevorderend effect kan hebben op tumor progressie5. Macrofagen hebben 
een groot aandeel in de samenstelling van dit micromilieu6. Deze zogenaamde tumor 
associated macrophages kunnen grofweg in twee categorieën verdeeld worden, namelijk 
de klassiek geactiveerde M1 macrofagen en de alternatief geactiveerde M2 macrofagen. 
Van deze twee categorieën zijn het de M2 macrofagen die tumorgroei bevorderende 
eigenschappen bezitten zoals stimulatie van angiogenese en het onderdrukkend van de 
immuunreactie die zich juist tegen de tumor richt7. Met behulp van immunofluorescente 
kleuringen tegen CD163, een specifieke marker voor M2 macrofagen, is de expressie van 
M2 macrofagen in twintig retrospectief geanalyseerde vestibularis schwannomen bepaald. 
Daarnaast is de mate van angiogenese gescoord. De resultaten van deze kleuringen laten 
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zien dat sommige vestibularis schwannomen grote hoeveelheden M2 macrofagen bevatten. 
Tevens lijkt er een positieve relatie te bestaan tussen de mate van macrofagen expressie 
en angiogenese evenals tumorgroei snelheid. Deze resultaten zijn in lijn met de gedachte 
dat tumorinfiltrerende M2 macrofagen de progressie van vestibularis schwannomen 
bevorderen en daarmee vormen deze ontstekingscellen een potentieel aangrijpingspunt 
voor therapie. 
Hoofdstuk zes omvat een studie naar de rol van BCRP expressie als een mogelijke 
oorzaak van medicatie resistentie in een selectie van verschillende perifere zenuwschede 
tumoren. BCRP is een transmembran efflux transporter protein dat een belangrijke functie 
lijkt te bekleden in verschillende biologische barrières zoals de bloed-hersen-barrière 8,9. 
De expressie van dit eiwit is ook geassocieerd met medicatie resistentie in kanker10. Een 
immunohistochemische kleuring van BCRP is verricht op een tissue microarray die is 
samengesteld uit tweeëntwintig sporadische vestibularis schwannomen, tien plexiforme 
neurofibromen en achttien maligne perifere zenuwschede tumoren. De uitkomsten van 
deze studie demonstreren de expressie van BCRP in het vaatendotheel van een groot 
aantal van alle drie de soorten tumoren. Mogelijk is deze endotheliale expressie van BCRP 
een specifiek tumorkenmerk, maar het zou ook een overblijfsel van de bloed-zenuw-barrière 
kunnen betreffen. Hoe dan ook suggereren deze resultaten dat BCRP mogelijk de 
blootstelling van het onderliggende weefsel aan medicatie kan verlagen. Dit kan een 
onderdeel van de verklaring vormen waarom medicamenteuze therapie voor perifere 
zenuwschede tumoren, waaronder vestibularis schwannomen, wisselende effecten laat 
zien. Als deze hypothese klopt dan kan de inhibitie van BCRP eventueel de gevoeligheid 
voor medicatie van deze tumoren vergroten. 
Hoofdstuk zeven vormt het vervolg op de macrofagen analyse die in hoofdstuk vijf is 
beschreven. Deze studie omvat dezelfde patiënten groep en focust op twee cytokinen, 
M-CSF en IL34. Van deze twee eiwitten is bekend dat ze een regulerende functie hebben 
met betrekking tot het activeren van macrofagen. M-CSF staat voor macrophage colony 
stimulating factor en is een cytokine dat macrofagen richting een M2 fenotype kan 
polariseren. De exacte tumor biologische karakteristieken van dit eiwit zijn nog niet geheel 
duidelijk maar er zijn verscheidenen tumor modellen waarbinnen het een rol lijkt te spelen 
bij macrofaag geassocieerde tumor progressie 11,12. IL-34, interleukine-34, is een eiwit dat 
veel overeenkomstige kenmerken met M-CSF vertoond 13,14. Relatief recente studies laten 
zien dat IL-34 op een vergelijkbare wijze als M-CSF tumor progressie kan stimuleren15. 
Onze studie demonstreert de expressie van deze twee cytokinen in vestibularis 
schwannomen. In overeenstemming met de verwachte functie van M-CSF wordt een relatie 
gezien tussen de mate van M-CSF expressie, de aanwezigheid van M2 macrofagen en 




de observatie dat IL-34 in alle tumoren in aanzienlijke mate aanwezig is toch suggestief 
voor het feit dat ook dit eiwit een rol speelt in de tumor biologie van het vestibularis 
schwannoom. De resultaten van deze studie lijken in lijn met de hypothese dat het 
inflammatoire micromilieu binnen het vestibularis schwannoom een belangrijke rol speelt 
in de progressie van deze tumoren. Daarmee vormen M-CSF, en wellicht ook IL-34, 
potentiële aangrijpingspunten voor toekomstige therapie. 
Conclusie
Het algemene doel van dit proefschrift is het ontrafelen van de biologische achtergrond van 
de klinische progressie van sporadische vestibularis schwannomen. In het geval van 
vestibularis schwannomen wordt progressie gemeten op basis van toename in tumor 
omvang. De meest voor de hand liggende factoren die het volume van vestibularis 
schwannomen bepalen zijn cel groei en cyste vorming. De resultaten van onze studies 
duiden er op dat intratumorale ontsteking op verschillende vlakken de progressie van deze 
tumoren beïnvloed. Door het stimuleren van angiogenese en de inhibitie van de 
immuunreactie gericht tegen tumorcellen stellen tumor associated macrophages sommige 
tumoren mogelijk in staat snellen en tot een groter volume te groeien. Daarnaast zou het 
goed mogelijk kunnen zijn dat de bulk van het ontstekingsinfiltraat op zichzelf al bijdraagt 
aan het volume van de tumoren. Het lijkt er op dat M-CSF en IL-34 een rol spelen in het 
reguleren van deze ontstekingsreactie waardoor ze potentieel een aangrijpingspunt kunnen 
vormen voor medicamenteuze therapie. Deze uitkomsten dienen uiteraard omzichtig 
geïnterpreteerd te worden. Het is belangrijk om te benoemen dat de resultaten van de 
vergelijkingen die we gemaakt hebben bestaan uit observaties van verschillende associaties. 
Het is daarbij altijd mogelijk dat deze resultaten nevenverschijnselen van een overkoepelend 
proces betreffen en in dat geval niet direct aan elkaar gerelateerd zijn. Voordat experimentele 
behandeling van patiënten met medicijnen die het intratumorale ontstekingsproces 
moduleren gestart kan worden is het dan ook nodig deze bevindingen in in vitro- en 
diermodellen te bevestigen. Mogelijke voorbeelden van dit type medicijnen zijn PLX3397 
(Pexidartinib) en RG7155 (Emactuzumab) 16,17. Beide zijn in staat macrofagen activiteit in 
tumoren te blokkeren en vormen om die reden ook potentiele behandelopties voor 
vestibularis schwannomen.
In de zoektocht naar nieuwe medicatie die tumorgroei van vestibularis schwannomen kan 
beïnvloeden is het belangrijk om mee te nemen dat de bevindingen van deze studie laten 
zien dat deze tumoren mogelijk “beschermd” worden door barrière eiwitten zoals BCRP. 
Toekomstig onderzoek moet rekening houden met dit potentiele extra obstakel om de 
effectiviteit van nieuwe behandelingen te kunnen optimaliseren. 
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Naast het vinden van nieuwe farmacologische manieren om vestibularis schwannomen te 
behandelen zijn er nog een aantal andere klinische dilemma’s die meer onderzoek 
behoeven. Een belangrijk onderwerp dat verder onderzocht moet worden is de potententiele 
superioriteit van protonen bestraling boven de reguliere fotonen bestraling. De huidige 
literatuur over dit onderwerp is tot op heden niet doorslaggevend en meer klinische trials 
zijn nodig om deze vraag te beantwoorden. De verdere ontwikkeling van nieuwe 
therapeutische behandel opties heeft ook effect op de gezamenlijke besluitvorming tussen 
arts en patiënt. Om deze besluitvorming blijvend te optimaliseren is onderzoek naar kwaliteit 
van leven van groot belang zodat de uiteindelijke behandeling het beste op de individuele 
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